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Abstract

Study Purpose: The purpose of this study was to examine whether there were differences in
patterns of care between African American (AA) and Non-Hispanic White (NHW) men newly
diagnosed with prostate cancer in Florida, and how the treatment patterns compare with the
National Comprehensive Cancer Network (NCCN) initial treatment recommendations.
Materials and Methods: This retrospective cohort study utilized data from the Florida Cancer
Data System (FCDS), to identify incident cases of prostate cancer diagnosed between 1982 and
2012. The variables of interest included: race/ethnicity, marital status, age at diagnosis, stage at
diagnosis, tumor grade, year of diagnosis, and treatment modality (singular or multimodality).
Adjusted odds ratios (AORs) and 95% confidence intervals were calculated to determine
disparities in the receipt of treatment by age at diagnosis, stage at diagnosis and tumor grade
between AA and NHW men.
Results: A total of 244,449 AA (30,556 cases or 12.5%) and NHW (213,893 cases or 87.5%)
men met the study inclusion/exclusion criteria. AA men were significantly less likely to receive
surgery only or surgery in combination with other treatment modalities compared to NHW men,
localized disease (AOR=0.66, 95% CI (0.63-0.68), regional disease (AOR=0.63, 95% CI (0.570.71), distant disease (AOR=0.50, 95% CI (0.34-0.75). Comparisons of adherence to the
NCCN initial treatment recommendations indicate that AA men with <10 years of life expectancy
had a lower NCCN initial treatment adherence percentage compared to NHW men (5% versus
vii

13%). Moreover, AA men in the very high risk group had a higher NCCN initial treatment
adherence percentage compared to NHW men (76% versus 70%).
Conclusion: After adjusting for potential demographic and clinical confounders, significant
differences exist in the receipt of first course of treatment where AA men were more likely to
receive radiation and/or hormone therapy and less likely to receive surgery compared to NHW
men. Further research is needed to address this disparity.
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CHAPTER ONE: INTRODUCTION
Geographic Variation in Prostate Cancer (PrCa)
Internationally, PrCa is the one of the most commonly diagnosed cancers among men,
second only to lung cancer (IARC, 2008). In 2008, Australia and New Zealand had the highest
age-adjusted incidence rate of PrCa at 104.2 per 100,000 men while South and Central Asia
had the lowest age-adjusted incidence rate at 4.1 per 100,000 men (IARC, 2008). To show
variability of prostate cancer incidence within the same continent, men in Southern Africa had
an age-adjusted incidence rate of PrCa of 61.8 per 100,000 men while Northern African men
had an age-adjusted incidence rate of 10.5 per 100,000 men (IARC, 2008). In the United States
(U.S.), the American Cancer Society (ACS) estimated ~1.7 million newly diagnosed reportable
cancer cases in 2013, with 28% of the newly diagnosed cases expected to be men with PrCa
(ACS, 2013).
Race/Ethnic Differences in PrCa Incidence and Mortality
Stratifying the PrCa incidence rates by race and ethnicity, African American (AA) men in
the U.S. have the highest incidence of PrCa at 236 per 100,000 men while Hispanic men have
the lowest PrCa incidence at 126 per 100,000 men, Table 1 (SEER, 2011).
The age-adjusted incidence rate of PrCa in Florida from 2005-2009 was 137.7 per
100,000 men (ACS, 2013). The state with the highest age-adjusted incidence rate of PrCa was
the District of Columbia (D.C.) with 185.1 per 100,000 men while Arizona had the lowest ageadjusted incidence rate of PrCa with 118.1 per 100,000 men (ACS, 2013). In Florida, from 1981
to 2008 the incidence gap of PrCa between AA men compared to White men has steadily
1

increased (Ren et al, 2012). Comparing the incidence rate of PrCa in Florida to the incidence
rate of PrCa globally, Florida has a high age-adjusted incidence rate of PrCa; therefore, this
study will focus on the burden of PrCa disease in Florida.
Table 1. Summary of Surveillance Epidemiology and End Results (SEER) Cancer and PrCa
Incidence Rates per 100,000 men by Race and Ethnicity in the U.S., 2005-2009.
Race/Ethnicity

Cancer Incidence
Rate*

PrCa Incidence Rate

All Races

541.0

154.8

Asian/Pacific Islander

342.6

146.9

Black

626.1

236.0

Hispanic

360.2

125.9

White

543.6

146.9

Source: SEER, 2011
*All cancers included
In terms of mortality, men in the Caribbean Islands have the highest PrCa mortality rate
at 26.3 per 100,000 men while Asian men have the lowest PrCa mortality rate at 2.5 per
100,000 men (IARC, 2008). In the U.S., over 580,000 cancer deaths were expected in 2013
with 10% of the cancer deaths attributed to PrCa (ACS, 2013). In addition, U.S. AA men have
the highest PrCa mortality rate at 53 per 100,000 men while Asian/Pacific Islander men have
the lowest PrCa mortality rate at 10 per 100,000 men, Table 2 (SEER, 2011).
Evaluating the PrCa mortality rates by U.S. state and/or territory, men in D.C. had the
highest age-adjusted mortality rate of 41.3 per 100,000 men while men in Hawaii had the lowest
age-adjusted mortality rate of 16.2 per 100,000 men (ACS, 2013). The age-adjusted mortality
rate of PrCa in Florida from 2005-2009 was 19.6 per 100,000 men (ACS, 2013). Lastly, AA
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men diagnosed with PrCa in Florida have a higher mortality rate compared to White men (Ren
et al, 2012).
Table 2. Summary of SEER Cancer and PrCa Mortality Rates by Race and Ethnicity per
100,000 men in the U.S., 2005-2009.
Race/Ethnicity

Cancer Mortality Rate*

PrCa Mortality Rate

All Races

222.4

23.6

Asian/Pacific Islander

132.6

10.0

Black

296.5

53.1

Hispanic

150.5

17.8

White

222.5

21.7

Source: SEER, 2011
*All cancers included
Disparities in Survival and Stage at Diagnosis for Patients with PrCa
In addition to the race and ethnic differences in incidence and mortality among men
diagnosed with PrCa, the same disparity trend is observed in the relative PrCa survival time and
stage of disease at diagnosis. The relative PrCa survival among AA men is lower at 1 year, 5
years and 10 years compared to other race and ethnic groups (SEER, 2012). Brawley and
colleagues suggest that AA men have a poorer PrCa survival rate compared to White men
because of a lack of access to quality health care and a lack of access to cancer related
treatment (Brawley, 1999). Five years later, Ward and colleagues emphasized these socioeconomic barriers when they evaluated cancer disparities by race/ethnicity and socioeconomic
status (SES) (Ward, 2004). For example, they identified low income, not graduating from high
school, inconsistent source of health insurance and not having recommended cancer screening
tests as reasons for the disparities in contributing to the increase in the cancer mortality rate
among minorities (Ward, 2004).
3

Approximately 80% of all PrCa tumors are diagnosed at localized stage (SEER, 2012);
indicating that the disease is confined within the prostate gland and has not metastasized.
However, AA men are more likely to be diagnosed with advanced disease (SEER, 2012), which
indicates that the disease has spread beyond the prostate gland. From a clinical perspective
this is pertinent because stage at diagnosis is an important predictor of survival, and informs
treatment recommendations (Hoffman RM et al, 2001). The current literature shows an
increase in the number of AA men that do not seek or obtain preventive health care in order to
detect PrCa at an early stage (Ward et al, 2004; Hoffman et al, 2001; Roetzheim et al, 1999;
Shavers et al, 2002). PrCa has a disproportionately high burden among AA men in the U.S.
and Florida because they are more likely to have a higher incidence rate, higher mortality rate,
more likely to be diagnosed with advanced disease at diagnosis, more likely to be diagnosed at
a younger age and less likely to live longer compared to White, Asian and Hispanic men (SEER
FastStats, 2012).
Disparities in Treatment for Patients with PrCa
The treatment modalities administered to PrCa patients have been shown to vary, with
advanced stage patients being under-treated and early stage patients being over treated
(Cooperberg, 2010; CECS, 1999; Shahinian et al, 2006; Wilt et al, 2008; Moyer, 2012; Shimer,
2013). In addition, the decision making process regarding treatment is influenced by the patient
and physician treatment preferences. For example, the physicians’ knowledge of multiple
treatments, willingness to suggest more than one treatment and/or proficiency to perform more
than one treatment have been shown to influence physician treatment preferences (O’Connor,
2004; Wennberg, 2011; McCoy et al, 1995). Among 900 men in Florida 65 years of age and
older it was determined that AA men were less likely to have a digital rectal examination (DRE)
compared to White men and the contributing factors for not having the DRE was a
4

misconception, by the patient, that it was not necessary or there were no medical issues to
justify a need for the DRE (McCoy et al, 1995). Mettlin and colleagues analyzed treatment data
from the National Cancer Data Base (NCDB) among newly diagnosed PrCa patients in the U.S.
and determined that AA men were more likely to elect no treatment and less likely to consent to
radical prostatectomy as part of first course of treatment compared to White men (Mettlin et al,
1997). There were no differences in the percentage of AA and White men that elected to have
radiation therapy; however, the authors concluded that more work is needed because there is
variation in PrCa treatment modalities by race, age and geographic region (Mettlin et al, 1997).
Powell and colleagues determined that race/ethnicity is dependent on age at diagnosis, stage of
disease and year of diagnosis and this guides the treatment outcome for patients with prostate
cancer (Powell et al, 2004)
Summary of PrCa Disparities
There are many reasons why health-seeking behaviors among AA men may not be
similar to Non-Hispanic White (NHW) men or men in other race/ethnic groups. For example,
there are various social determinants, psychosocial factors and health-seeking related
behaviors that play a role in men being diagnosed at an early stage versus an advanced stage
(Ward et al, 2004; Hoffman et al, 2001; Roetzheim et al, 1999; Shavers et al, 2002; Lintz et al,
2003). For example, men diagnosed with advanced stage PrCa are more likely to be depressed
prior to their diagnosis (Lintz et al, 2003). In addition, access to a specialist such as a
genitourinary oncologist, proximity of primary residence to the closest health facility, fear of the
unknown, fear of healthcare professionals, fear of dying, fear of invasive or surgical procedures,
fear of having a DRE, lack of healthcare professionals that look like the patient, history of
discrimination (i.e. Tuskegee Syphilis Study) and the lack of available transportation all play a
role in AA men being diagnosed at an early stage versus advanced stage (Ward, 2004;
5

Shavers, 2002, Shavers, 2004). Moreover, Jones and colleagues indicate that racial
differences in stage at diagnosis for PrCa cases is significantly correlated with education,
occupational rank and not fully understanding insurance coverage (Jones et al, 2008). In
addition, Potischman and colleagues hypothesize that hormonal exposures in utero to
testosterone and progesterone may contribute to disparities in cancer risk (Potischman et al,
2005). For example, the authors collected serum at the first prenatal visit and determined that
AA women had higher hormone concentrations of androstenedione, testosterone, estradiol and
progesterone compared to Hispanic and Caucasian women (Potischman et al, 2005). Stratifying
the results by years of education, AA women still had higher concentrations of the same
aforementioned hormones compared to Hispanic and Caucasian women (Potischman et al,
2005). This study suggests that further research is needed regarding the mother’s exposures,
in utero hormonal exposures, and the impact of the mother’s exposure over time to the child.
All of the aforementioned factors have not been shown to solely explain why AA men
with certain demographic and clinical characteristics have an increased risk of developing PrCa
versus NHW men nor have the factors been shown to solely determine why AA men are more
likely to be diagnosed at an advanced stage.
There is a gap in the current literature regarding the first course of
treatment/management strategies received by AA men in Florida newly diagnosed with PrCa, by
age at diagnosis and stage at diagnosis/tumor grade, and how the first course of
treatment/management strategies compare to NHW men. Furthermore, it is unknown how the
treatment modalities administered compare to the treatment recommendations of the National
Comprehensive Cancer Network (NCCN). This study explored the differences in
treatment/management strategies among AA and NHW men in Florida newly diagnosed with
PrCa.
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Public Health (PH) Importance of PrCa
Florida has the third highest number of new cancer cases in the U.S., behind California
and Texas (ACS, 2013). AA men have been identified as a high risk group for developing PrCa
(AUA, 2013; ACS, 2000) and various studies have evaluated race/ethnic differences in
treatment patterns among PrCa patients using state and national databases (Shavers et al,
2004; Mettlin, 1997; Polednak and Flannery, 1992; Shimer, 2013); however, published studies
that have evaluated race/ethnic differences in treatment patterns of PrCa patients in the State of
Florida are lacking. This study will inform healthcare professionals in Florida who work with and
provide care to PrCa patients about the treatments that their patients receive or do not receive
based on the NCCN treatment recommendations. In addition, this study will inform PrCa
patients about the treatment modalities that are administered and how the patterns of care
compare to the NCCN treatment recommendations. The results of this study are generalizable
to men newly diagnosed with PrCa who received all or part of their first course of treatment in
the State of Florida and their data is reported to the Florida Cancer Data System. The results of
the study can be used to educate clinicians, healthcare professionals, and patients on the
race/ethnic treatment disparities in Florida among patients newly diagnosed with PrCa.
Research Hypotheses and Specific Aims
Hypothesis 1
There are differences in the first course of treatment patterns between AA men and NHW men
newly diagnosed with PrCa in Florida by stage at diagnosis/tumor grade and age at diagnosis.
Aim 1
To compare the first course of treatment modalities received by newly diagnosed PrCa
patients in Florida between AA and NHW men with the same stage at diagnosis/tumor
grade and age at diagnosis.
7

Hypothesis 2
The treatment modalities administered to AA men and NHW men newly diagnosed with PrCa in
Florida may differ from recommended treatment as per NCCN guidelines among men with the
same stage at diagnosis/tumor grade, age at diagnosis and life expectancy.
Aim 2
To determine if the treatment modalities administered to AA men and NHW men differ
from the treatment recommendations of the NCCN among men with the same stage at
diagnosis/tumor grade, age at diagnosis and life expectancy.
Study Purpose
This study was designed to enhance the current body of knowledge as it relates to
detectable differences in treatment strategies among AA and NHW men in Florida newly
diagnosed with pathologically confirmed PrCa and to assess how these strategies embody the
contemporary NCCN treatment recommendations.
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CHAPTER TWO: LITERATURE REVIEW
Study Background and Rationale
Anatomy of the Prostate Gland
Signaled by androgens, specifically testosterone, which is produced in the scrotum, the
prostate gland is part of the male reproductive system and starts developing before birth and
continues to grow throughout puberty, with growth of the prostate gland slowing down at
adulthood (ACS, PC Overview, 2013). Anatomically located inferior to the bladder and anterior
to the rectum, the purpose of the prostate gland is multi-faceted. First, the prostate gland aids
in creating fluid that protect and nourish the sperm (ACS, PC Overview, 2013). Secondly, the
prostate gland, working with the nervous system, serves as a valve to release sperm or urine
(ACS, PC Overview, 2013).
The type of tissue that comprises the prostate gland is primarily epithelial tissue.
Bostwick and colleagues indicate that approximately 95% of the PrCa tumors arise from the
epithelial cells producing histology of adenocarcinoma (Bostwick et al, 1989). Adenocarcinoma
of the prostate gland was the focus of this study; the rare PrCa histologic types that comprise
5% of PrCa cases, such as mucinous, ductal, neuroendocrine and small cell carcinoma were
not addressed (Bostwick et al, 1989).

9

Figure 1. Anatomy of the Prostate
Picture retrieved from the American Cancer Society on August 15, 2013
(http://www.cancer.org/cancer/prostatecancer/detailedguide/prostate-cancer-what-is-prostatecancer) “Reprinted by the permission of the American Cancer Society, Inc. All rights reserved”
as set forth on Exhibit A.
Prostate specific antigen (PSA) test
The PSA test is a blood test that quantifies the amount of the protein, called PSA, in the
prostate gland (Garnick, 2012). In 1986, the Federal Drug Administration (FDA) approved the
use of the PSA test for continuous monitoring of PrCa disease progression and in 1994 the PSA
test was approved to be used along with the digital rectal examination (DRE) to test for PrCa in
men with no clinical symptoms (Littrup et al, 1992; NCI, 2012). An elevated PSA level is
considered to be above 4.0 ng/mL; however, Henderson and colleagues suggest differences in
race specific reference PSA values where AA men have a statistically significant higher normal
PSA level compared to White men (Henderson et al, 1997). In a study conducted among
military men, Moul and team concluded that AA men newly diagnosed with PrCa had
statistically significant higher PSA values at the time of diagnosis compared to White men,
p<0.001 (Moul et al, 1995). In addition, Thompson and colleagues suggest there is no
consensus on the PSA normal upper limit (Thompson et al, 2004). On the other hand, 300
Turkish men were administered a transrectal ultrasound (TRUS) biopsy of the prostate if they
10

had an abnormal DRE or a serum PSA over 2.5 ng/ml (Eskicorapci et al, 2004). Internationally,
this suggests no consensus on the PSA normal range and if the PSA normal upper limit should
be standardized by race/ethnicity. Therefore, based on the results of the receiver operating
characteristic (ROC) curve, Thompson et al recommend multiple PSA measurements over a
period of time versus a single PSA measurement in order to determine if a PSA value is
elevated or not (Thompson et al, 2005). This methodology allows clinicians to determine the
normal upper limit for each individual patient, regardless of race/ethnicity.
In addition to there being no consensus on the PSA normal upper limit, there is also
controversy on whether the PSA test is used to potentially over diagnose or over treat low risk
prostate tumors due to the potential risks to the patient outweighing the benefits (Moyer, 2012;
Carroll P et al, 2009; Wolf, 2010; Lim et al, 2008; Barry, 2009). For example, an elevated PSA
level does not equate to a man having PrCa (Moyer, 2012). Men with confirmed prostatitis,
urinary tract infection (UTI), benign prostatic hyperplasia (BPH), and men with prior history of a
biopsy or prostatectomy have been shown to have an elevated PSA level (Dalton, 1989; Neal et
al, 1992; Collins et al, 1993; Nadler et al, 1995; Ulleryd et al, 1999). Also, Barry suggests that
only a quarter of men had PrCa out of those who had a prostate biopsy after confirmation of an
elevated PSA value (Barry, 2001). Does this mean that 75% of the men in the study with an
elevated PSA value were potentially over treated? The verdict has yet to be determined.
The United States Preventative Services Task Force (US PSTF) recommend that all
men regardless of age should not have PSA screening because it will lead clinicians to over
treat patients for PrCa that may not cause any major symptoms that warrant any type of
invasive treatment (Moyer, 2012). The US PSTF recommendation is that an elevated PSA
value does not indicate that a man will develop a tumor that is clinically significant (Moyer,
2012). One of the major limitations with the US PSTF recommendation is that there is no
differentiation in the recommendation for low risk versus high risk men, all men are categorized
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together, regardless of risk (Moyer, 2012). On the other hand, the American Urological
Association (AUA) updated their PrCa screening recommendation in April 2013 and added a
recommendation for PSA screening by age (AUA, 2013). For example, the AUA does not
recommend PSA screening among men 40 years of age and younger as well as no annual PSA
screening among men 40 to 54 years of age (AUA, 2013). In addition, the AUAs prostate
screening recommendation for high risk men is that it should be addressed on a case by case
basis (AUA, 2013). The ACS has a different recommendation from the US PSTF and AUA
regarding PrCa screening and they provide additional detail on recommendations for high risk
groups (ACS, 2013). For example, the ACS state that it is pertinent for every male to have a
discussion with a healthcare professional before making any treatment decisions (ACS, 2013).
In order to determine the best course of action for screening, AA men should start this
discussion at age 45 since they are more likely to be diagnosed with PrCa before the age of 50,
while men with more than one first degree relative diagnosed with PrCa should start this
discussion at age 40 (ACS, 2013). Based on the aforementioned recommendations from the
US PSTF, AUA and ACS there is no documented consensus for PSA screening among high
risk or AA men at the national level.
Andriole and colleagues with the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer
Screening Trial determined that the rate of death from PrCa was similar among the case group
and the control group when evaluating men who had an annual PSA screening (Andriole et al,
2012). One limitation for this study is that there was no stratification by race/ethnicity in order to
determine if the rate of death from PrCa was similar between race/ethnic groups. On the other
hand, the European Randomized Study of Screening for Prostate Cancer (ERSPC) concluded
that men who had a PSA screening had a decreased rate of death from PrCa compared to
those who had no PSA screening (Schroder et al, 2012). The conclusion of these population
based studies having opposite or different results adds to the current controversy on whether
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the PSA test should be utilized as a screening tool. Garnick state that the PSA test should be
primarily used, from a clinical perspective, after a man has been diagnosed with PrCa versus
using it as a screening tool to identify PrCa (Garnick, 2012).
Another concern with utilizing the PSA test as a screening tool is that it lacks the ability
to differentiate between aggressive prostate tumors versus slow growing prostate tumors
(Garnick, 2012; Moyer, 2012; Hill, 2013). From a clinical perspective, this lack of detail with the
PSA test further convolutes the controversy on the use and benefit of the PSA screening test.
Hill and colleagues conducted a case control study among military men to determine if there
were any clinical laboratory biomarkers that could be used in conjunction with the PSA test to
obtain a clinical rule for administering a prostate biopsy (Hill, 2013). The authors determined
that hemoglobin count, red blood cell count, serum creatinine count, the mean corpuscular
volume and AA race were significantly associated with PrCa stages 2 through 4 compared to
stage 1 (Hill, 2013). From a clinical perspective, this study contributed to the current body of
knowledge because the additional clinical laboratory biomarkers may be used to clinically
determine aggressive versus non-aggressive tumors which may allow clinicians to make
appropriate treatment decisions and/or recommendations.
In summary, Garnick suggest that PSA screening followed by delayed treatment may be
a feasible compromise to the current controversy on the effectiveness of the PSA screening test
(Garnick, 2012); however, the verdict has yet to be determined because this forethought in
delaying treatment may not be wise for all men diagnosed with PrCa, especially for high risk or
AA men.
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Diagnosis of PrCa
Although there is controversy around the use of the PSA test as a screening tool, the
PSA test, the DRE and a biopsy of the prostate are the current methods being used to diagnose
PrCa (Schroder et al, 1998; Littrup et al, 1994). Combined reviews of both the PSA test and the
DRE results provide a clinician with guidance to make prognostic and treatment
recommendations if one or both test results are abnormal or positive (Moyer, 2012; Garnick,
2012). In addition, other factors such as age and life expectancy are also considered
(Stangelberger et al, 2008; Albert and Clark, 2008; Moul and Mouraviev, 2008). For example,
considering the other demographic and/or clinical factors, if one or both test results are positive
or abnormal then a clinician may recommend a TRUS guided needle biopsy of the prostate to
confirm the presence of cancer (Garnick 2012; Moul and Mouraviev, 2008). Eskew and
colleagues performed a TRUS on patients if the DRE was abnormal or if the PSA result was
above 4.0 ng/ml among 100 patients within a year to compare the 5 region biopsy methodology
and the sextant biopsy methodology (Eskew, 1997). If the biopsy result is positive for cancer
then the physician may recommend invasive or non-invasive first course of treatment options.
Treatment Modalities
After a patient has pathologic confirmation of PrCa it is important to evaluate all potential
treatment options which are guided by multiple clinical factors such as clinical tumor node and
metastasis (TNM) stage, age of the patient at diagnosis, and life expectancy (Netto and Cheng,
2012; Moyer, 2012). The treatment options that are available for men diagnosed with PrCa
include watchful waiting, active surveillance, cryosurgery, surgery (prostatectomy), radiation,
hormone therapy, chemotherapy or immunotherapy (ACS, 2013). Watchful waiting, active
surveillance, surgery or radiation are treatment options that are commonly administered to men
diagnosed with early stage or localized PrCa while men diagnosed with regional, advanced or
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metastatic PrCa are commonly administered hormone therapy, chemotherapy, or
immunotherapy (Mettlin et al, 1997; Polednak and Flannery, 1992; Shavers et al, 2004;
Cooperberg et al, 2010; Albertsen et al, 1998). Cryosurgery has been used to treat both
localized and advanced PrCa (Henderson and Davies, 2012). In reviewing the literature,
advanced stage PrCa or PrCa disease progression is known by but not limited to the following
nomenclature: “castrate-resistant”, castration-recurrent”, “hormone resistant” and “androgeninsensitive” (Hotte and Saad, 2010). These nomenclature were utilized in the literature search
in order to understand the treatment options for men diagnosed with advanced PrCa since AA
men and high risk men are more likely to be diagnosed with advanced stage disease at
diagnosis (SEER, 2011; ACS, 2013).
Watchful Waiting versus Active Surveillance
Watchful waiting or expectant management is defined as not receiving any type of
invasive or non-invasive treatment after being diagnosed with localized PrCa while active
surveillance is defined as actively following and monitoring a PrCa patient with annual DREs,
PSA tests and prostate biopsies (Ip S et al, 2011; ACS, 2013). One of the fundamental
differences between watchful waiting and active surveillance is that the intention of active
surveillance is curative while the intention of watchful waiting is palliative (Ip S et al, 2011). The
goal of active surveillance is to monitor the prostate gland to determine if the tumor is slow or
rapidly growing (Prostate Cancer Foundation, www.pcf.org, 2014).
The reason for watchful waiting being considered palliative treatment and not curative is
that treatment usually administered after the first course of treatment plan has been
implemented is considered to be subsequent or non-first course of treatment (FCDS DAM,
2013); therefore, treatment administered after the watchful waiting time period is considered
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disease progression. Appendix A describes the first course of treatment and how watchful
waiting is defined, according to FCDS.
The similarity between watchful waiting and active surveillance is that pathologic
confirmation of PrCa has been established; however, the decision or intent to treat the PrCa
was delayed (Garnick, 2012). In December 2011, the National Institutes of Health (NIH)
recognized active surveillance as a possible treatment option for men with ‘low-risk PrCa’
(Garnick, 2012).
In a meta-analysis using data from the U.S., Sweden, Israel, and Scotland, Chodak and
colleagues suggest watchful waiting as a feasible treatment option for men diagnosed with
grade 1 or grade 2 prostate cancer with a life expectancy of 10 years or less (Chodak et al,
1994). However, for men with a life expectancy longer than 10 years, watchful waiting is not
recommended because the risk of living with metastatic PrCa increases (Chodak et al, 1994).
Cryosurgery
Cryosurgery is a surgical procedure where probes (cryoprobes) are used to freeze and
defrost the entire prostate gland or part of the prostate gland where the foci of tumor is located
using argon gas (freeze) and helium gas (defrost) (Rees et al, 2004; Harvey, 2006; Henderson
and Davies, 2011).

Cryosurgery can be used as a single freeze-defrost method or a double

freeze-defrost method (Henderson and Davies, 2011). Cryosurgery has been used to treat
PrCa that is localized, regional, advanced, and as salvage treatment after failed radiation (Rees
et al, 2004; Harvey, 2006; Henderson and Davies, 2011); however, there is currently no gold
standard in which cryosurgery should be performed (Rees et al, 2004; Harvey, 2006;
Henderson and Davies, 2011). When the procedure was first introduced in the 1960s, it was
not well accepted because of the ‘high complication rates’ and the PrCa recurrence rate was
greater than 70% (Rees et al, 2004). The side effects versus benefits of cryosurgery have also
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been evaluated. For example, erectile dysfunction is the primary complication affecting up to
96% of the men who have cryosurgery (Henderson and Davies, 2011). In addition, the ACS
report that 4 out of 5 men have damage to the nerves surrounding the prostate gland after
surgery (ACS, 2013).
Surgery
A prostatectomy is the surgical removal of the prostate gland and there are different
facets of a prostatectomy such as a subtotal prostatectomy where the prostatic capsule may or
may not be left intact, a radical or total prostatectomy where the prostate, prostatic capsule,
ejaculatory ducts and seminal vesicles are removed and a prostatectomy that involve the
removal of other organs such as the bladder (ACS, 2013; FCDS DAM, 2013). The details of the
prostate cancer surgeries are discussed in Chapter 3.
Currently there is no consensus on the best treatment modalities for early stage or
localized PrCa patients (Moyer, 2012; Xiao et al, 2013). Bill-Axelson and colleagues randomly
assigned early stage PrCa patients to receive surgery or watchful waiting (Bill-Axelson, 2005).
After 10 years of follow-up, the authors concluded that the patients randomized to receive
surgery had a lower risk of death compared to the patients randomized to the watchful waiting
group (Bill-Axelson, 2005). Utilizing SEER-Medicare linked data, Shavers and team concluded
that 30% of AA men chose watchful waiting as a treatment option while 23% of White men
chose watching waiting as a treatment option (Shavers, 2004). After adjusting for potential
confounders, the OR associated with the aforementioned conclusion that AA are more likely to
select watchful waiting as a treatment option was statistically significant (compared AA men to
White men), OR = 1.4, 95%CI (1.3, 1.6).

AA men are twice as likely to be diagnosed with

advanced disease (Jones et al, 2008); therefore, this information suggest that AA men may not
be well informed or educated in selecting the most appropriate treatment option because they
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are more likely to select watchful waiting which is a palliative treatment option. Based on the
long term follow-up results from the study conducted by Bill-Axelson and colleagues, those who
select watchful waiting have a higher risk of death compared to those who had surgery (BillAxelson, 2005). In essence, AA men are more likely to select a treatment option where the risk
of death is higher compared to White men.
One of the suggested barriers to men selecting a more invasive treatment option such
as surgery is the potential for impotence. For example, Murphy and colleagues determined that
~60% of patients who had a radical prostatectomy were impotent after surgery when they were
not impotent before surgery (Murphy et al, 1994). Additionally, in a study of quality of life of
PrCa patients on Medicare, results from 1,000 men indicate incontinence affected their quality
of life more than erectile dysfunction (Fowler et al, 1995). Despite this, ~90% of the men would
choose to have surgery again (Fowler et al, 1995). A limitation of this study was that the results
were not stratified by race/ethnicity in order to determine if there were race/ethnic differences in
the percentage of men that would choose to have surgery again.
Radiation Therapy or Radiotherapy
Radiation therapy or Radiotherapy is defined as the administration of radiation beams to
the body (ACS, 2013). There are 2 main types of radiation, external beam radiation and
brachytherapy (internal radiation therapy) (ACS, 2013). For example, men with localized PrCa
usually receive external radiation beams to the prostate or radioactive ‘seeds’ are implanted in
the prostate to halt the spread of cancer outside of the prostate gland (ACS, 2013). Radiation
therapy can be administered in parallel with other treatment modalities such as surgery or
hormone therapy; where hormone therapy is used to shrink an enlarged prostate gland before
radiation therapy is administered (ACS, 2013). Radiation therapy is recommended as adjuvant
therapy after surgery if a patient has positive surgical margins (Leibovich et al, 2000). More
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specifically, administering radiation therapy in combination with surgery after confirmation of
positive surgical margins has been shown to extend the time to first recurrence (Leibovich et al,
2000). Laverdiere conducted a clinical trial where 100 patients with localized PrCa were
randomized into 1 of 3 groups to have radiation therapy only, hormone therapy before radiation
therapy (neoadjuvant therapy) or hormone therapy before, during and after radiation therapy
(Laverdiere et al, 1997). The group that had hormone therapy administered before, during and
after radiation therapy had a significant rate of lower positive prostate biopsies 12 months post
treatment (Laverdiere et al, 1997).
Hormone Therapy
Hormone therapy for PrCa patients is primarily for men with disease progression or
metastatic PrCa (Stangelberfer et al, 2008). Hormone therapy is also known as androgen
deprivation therapy or androgen suppression therapy (ACS, 2013) and can be administered to
shrink the prostate tumor before radiotherapy (Laverdiere et al, 1997). The hormone therapy
drugs target the testicles from producing androgens, called anti-androgen drugs, which are
usually taken orally (ACS, 2013). In some instances the testicles are surgically removed in
order to stop the production of androgens (ACS, 2013).
De Bono and team evaluated the survival time in patients that previously received
docetaxel to randomly receive abiraterone and prednisone or a placebo and prednisone (de
Bono et al, 2011). The results of the clinical trial indicate that the patients randomized to the
abiraterone and prednisone group had a longer survival by 4 months (de Bono et al, 2011).
From the same team, Ryan and colleagues evaluated abiraterone in patients with metastatic
PrCa that did not previously receive chemotherapy in a double blinded study that randomized
~1000 patients into two groups (Ryan et al, 2013). The first group received abiraterone and
prednisone while the second group received a placebo and prednisone (Ryan et al, 2013). The
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authors determined that the first group, those who received abiraterone and prednisone, had a
longer progression free survival compared to the second group by 8 months (Ryan et al, 2013).
In a double blinded study evaluating the use of enzalutamide after chemotherapy, ~1200
men were randomized to receive the drug or a placebo (Scher et al, 2012). The results of the
clinical trial indicate that the men who received enzalutamide had a longer survival by 5 months
compared to the placebo group (Scher et al, 2012). In a randomized clinical trial evaluating
bone metastasis in men with primary PrCa that may or may not have previously received
chemotherapy, Parker and colleagues administered radium 223 injections or a placebo injection
and determined that the patients who received the radium 223 injections had a longer survival of
3 months compared to those who received the placebo injections (Parker et al, 2013).
Chemotherapy
Chemotherapy is defined as the administration of drugs that have been designed to
attack and halt the growth cycle of cancer cells in the body and they are used to target prostate
cancer cells that have metastasized to other organs of the body (ACS, 2013). When men with
PrCa are administered chemotherapy this usually indicates that hormone therapy was not
successful (ACS, 2013). Tannock and colleagues randomly assigned advanced disease PrCa
patients who previously failed hormone therapy to receive docetaxel and predisone or
mitozantrone at multiple different dosage levels over varying time periods (Tannock et al, 2004).
The authors observed that the men randomized to receive docetaxel plus predisone every three
weeks had a statistically significant reduce rate of death of 24% compared to those in the
mitozantrone group (Tannock et al, 2004). On the other hand, Bahal and colleagues evaluated
the survival time among 2 groups of patients that received mitoxantrone or cabazitaxel among
metastatic PrCa patients (Bahl et al, 2013). The authors determined that patients who received
cabazitaxel lived longer compared to the patients who received mitoxantrone (Bahal, 2013).
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In summary, based on the aforementioned clinical studies, mitaxantrone has not been
shown to reduce the rate of death among men with advanced PrCa.
Immunotherapy
Immunotherapy for prostate cancer is administered in the form of vaccine therapy (ACS,
2013). The goal of the vaccine is to initiate the cells in the body to fight off the prostate cancer
cells and this treatment modality is administered to men with advanced prostate cancer or men
who have failed hormone therapy (ACS, 2013; Kantoff, 2010). Kantoff and colleagues
conducted a randomized clinical trial and determined that men who were administered
Sipuleucel-T (Sip-T) immunotherapy had a reduced rate of death by 20% plus they had a longer
survival of 4 months compared to men who did not receive Sipuleucel-T immunotherapy
(Kantoff, Higano et al, 2010). Kantoff and colleagues conducted another randomized phase 2,
blinded, clinical trial where they evaluated a pox viral vaccine and observed that men
randomized to the group to receive the poxvirus called “PROSTVAC-PF”, had a 40% reduced
rate of death and with a median survival time of 10 months compared to the men who did not
receive the vaccine (Kantoff, Schuetz et al, 2010). As of 2010, Sip-T is the only Federal Drug
Administration (FDA) approved immunotherapy drug for prostate cancer (NCI, 2015).
Summary of PrCa Treatment Modalities
As previously mentioned, the PrCa treatment modalities can be delivered as a singular
treatment modality (i.e. radiation only) or the treatment options can be combined over a period
of time using multiple different treatment modalities (i.e. surgery and radiation). In addition, men
can receive multiple different types of the same treatment modality. For example, men can
receive external beam radiation and ‘seed’ implants (D’Amico et al, 1998). Men tend to opt for
less invasive treatments like watchful waiting or active surveillance versus more invasive
treatment such as surgery or radiation due to some of the potential risks or potential side effects
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of having an invasive procedure (Shavers, 2004). For example, the potential risks associated
with surgery include but are not limited to incontinence or impotence while the side effects
associated with radiotherapy include rectal bleeding and/or fecal soiling from the radiation
beams impacting the bladder and rectum (Garnick, 2012). In less than 5% of the patients that
have radiation, a fistula forms between the rectum and bladder where urine leaks from the
bladder to the rectum (Leibovich et al, 2000). In addition, the side effects from administering
hormone therapy, chemotherapy or immunotherapy include increased body weight, decreased
sex drive, hot flashes, heart irregularities, liver abnormalities and bone thinning (Garnick, 2012).
PrCa Risk Factors
There are various modifiable and unmodifiable risk factors associated with PrCa. For
example, the American Cancer Society (ACS) indicate that older age, AA men, men with a
family history of PrCa, genetic variations, obesity, men with diets that include a high proportion
of red meats or high fat dairy products, men with a positive history of sexually transmitted
infections such as chlamydia or gonohorrea and men with prostatitis (inflammation of the
prostate) have an increased risk of developing PrCa (ACS, 2012). This is a review of the
literature as it relate to the aforementioned risk factors.
Age
The Department of Defense (DOD) determined that there was a 119% increase in the
number of men diagnosed with PrCa younger than 60 years of age from 1991-2000 (DODCPDR, 1999). Scardino stated that 30% of men 50 years of age and older have histologic
confirmation of PrCa at the time of autopsy (Scardino, 1989). On the other hand, the
percentage of men with histologic confirmation of PrCa at autopsy was reported as 80% among
men 70 years of age and older (Breslow, 1977). This is a 167% increase among men 50 years
of age and older compared to those 70 years of age and older. AA men are twice as likely to
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be diagnosed with PrCa before age 50 compared to all race/ethnic groups (SEER FastStats,
2012). Table 3 shows the age-adjusted PrCa incidence rates by age at diagnosis among men
in the SEER 18 geographic regions.
Table 3. Age-Adjusted SEER PrCa Incidence Rates* by Age at Diagnosis, 2009 (SEER 18).
Age at Diagnosis

Race/Ethnicity

<50

50-64

65-74

75+

All Races

6.14

311.56

853.90

620.01

Asian

1.53

130.02

477.48

424.98

Black

14.34

551.17

1278.56

835.35

Hispanic

3.23

210.84

745.22

566.85

White

5.21

289.38

804.00

574.57

*per 100,000 and age adjusted to the 2000 US Std Population
In the study conducted by Shavers et al utilizing SEER-Medicare linked data, the results
indicate that AA men were younger at diagnosis compared to White Hispanic and White NonHispanic men with a mean age at diagnosis of 73.6 years, 74.4 years and 74.4 years,
respectively, (p-value <0.0001) (Shavers et al, 2004). The age at PrCa diagnosis is considered
to be an important clinical factor because age at time of diagnosis has been shown to influence
treatment options (Stangelberger et al, 2008).
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When comparing the overall first course of treatment modalities received using data from
the National Cancer Data Base (NCDB), men 18-64 years of age were more likely to receive
surgery (57%) compared to radiation or expectant management, while men 65-74 years of age
were more likely to receive radiation (42%) compared to surgery or expectant management and
men 75 years of age and older were more likely to receive expectant management (57%)
compared to surgery or radiation (Siegel et al, 2012).
Family History (Hx) of Cancer or PrCa
Spitz and colleagues conducted a hospital based case control study with approximately
800 age-matched PrCa cases and controls (Spitz et al, 1991). The patients were administered
a risk factor questionnaire and the risk of developing PrCa increased 3 fold among men with a
brother who had PrCa (Spitz et al, 1991). Steinberg and team had similar results after
conducting a case control study. They found that the cases were significantly more likely to
have a father or brother diagnosed with PrCa compared to the controls and the risk of a male
developing PrCa increased as the number of first degree relatives diagnosed with PrCa
increased (Steinberg et al, 1990). Likewise, Hayes and colleagues found similar results among
AA and White men living in Atlanta, Detroit and New Jersey. The authors concluded there was
a significant 3 fold increased risk of developing PrCa with a family history of PrCa among a first
degree relative, OR=3.2, 95%CI (2.0-5.0) (Hayes et al, 1995). In addition, the risk of developing
PrCa significantly increased 5 fold if a male had a brother with a history of PrCa, OR=5.3,
95%CI (2.3-12.5) (Hayes et al, 1995).
Gronberg and colleagues alluded to familial clustering of PrCa after evaluating over 90
families that had 3 or more first degree relatives diagnosed with PrCa (Gronberg, et al 1997).
The results of the study indicate a hereditary linkage of PrCa; however, the primary limitation of
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the study was no documentation in the manuscript that the study evaluated high risk groups
such as AA men (Gronberg, et al 1997).
Approximately 90 North American and Swedish families having a minimum of 3 first
degree relative diagnosed with PrCa were evaluated and the authors concluded there is a
hereditary linkage of PrCa on chromosome 1 with the men in the families having an age at
diagnosis of PrCa less than 65 years of age (Gronberg et al, 1997). One of the major limitations
of this study was no discussion that AA families were included in the study population. Yeager
and team identified chromosome 8q24 as being associated with PrCa risk in a genome-wide
association study (GWAS) (Yeager et al, 2007). In addition, Thomas and colleagues from the
same previous GWAS study group identified PrCa cases and controls by testing ~27,000 single
nucleotide polymorphism (SNPs) (Thomas et al, 2008). The authors suggest that the 3
significant loci identified on 2 SNPs may be used to identify high risk PrCA patients (Thomas et
al, 2008). One limitation of this study is that AA men were not represented in the study
population.
In summary, men with a family history of PrCa, especially those with an affected first
degree relative have an increased risk of developing PrCa. Also, approximately 35 SNPs have
been validated to be associated with PrCa, explaining 25% of the genetic risk associated with
PrCa (Aly et al, 2011). However, genetics does not solely explain why AA men are at a higher
risk of developing PrCa compared to White, Hispanic or Asian men.
Race and Ethnicity
AA men have a prostate specific incidence rate that is 1.6 times higher and 1.9 times
higher compared to White men, and Hispanic men, respectively (Howlader et al, 2011). The
prostate specific mortality rates show the greatest increase when comparing AA men to White
men (2.5 times higher) and Hispanic men (3 times higher) (Table 4).
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Table 4. Summary of SEER Cancer and PrCa Incidence and Mortality Rates by Race and
Ethnicity per 100,000 men in the U.S.
Cancer
Incidence
Rate*

PrCa
Incidence
Rate

Cancer
Mortality
Rate*

PrCa
Mortality
Rate*

Race/Ethnicity

Male

Male

Male

Male

All Races

541.0

154.

222.4

23.6

Black

626.1

236.0

296.5

53.1

Hispanic

360.2

125.9

150.5

17.8

White

543.6

146.9

222.5

21.7

Source: SEER, 2011
*All cancers included
**Compared to Black men
In addition to the differences in PrCa incidence and mortality by race and ethnicity, the
health disparity is further defined when considering stage at diagnosis. Table 5 below shows
that AA and Hispanic men have an overall higher incidence of being diagnosed with regional or
distant PrCa compared to White men (SEER FastStats, 2012). In essence, this indicates that
AA and Hispanic men are more likely to be diagnosed with PrCa at a stage where the cancer
has spread beyond the prostate to other areas of the body such as the lymph nodes and bone.
Table 5. SEER PrCa Incidence by Summary Stage at Diagnosis and Race/Ethnicity, per
100,000 men in the U.S.*
SEER Summary Stage at Diagnosis
Race/Ethnicity

Local

Regional

Distant

All Races

53.4

24.2

15.0

Black **

50.8

24.9

17.8
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Table 5 (Continued)
Hispanic^

49.9

25.8

18.0

White**

53.7

24.2

14.7

Source: SEER FastStats, 2012
*2000-2009
^Include all races
**Includes Hispanics
When evaluating race/ethnic differences and PrCa treatment patterns, Polednak and
Flannery conducted a study to evaluate treatment differences among Black and White patients
diagnosed with PrCa using the Connecticut Cancer Registry SEER Database (Polednak and
Flannery, 1992).

The authors determined that Black patients with advanced stage disease

were significantly less likely to receive surgery only (prostatectomy) compared to Whites, 4.7%
versus 0% respectively, p-value=0.009 (Polednak and Flannery, 1992). For all other treatment
options there were no significant differences among Blacks and Whites. On the other hand,
Shavers and colleagues conducted a study using SEER-Medicare linked data and determined
that AA and Hispanic men are significantly more likely to receive watchful waiting compared to
White men, adjusted OR (AA) = 1.3, 95%CI (1.1, 1.4) versus adjusted OR (Hispanic) = 1.2, 95%
CI (1.03,1.4) (Shavers et al, 2004). The authors defined watchful waiting as not receiving any
type of first course of treatment (no documentation that radiation, surgery or hormone treatment
was administered within the first 6 months after diagnosis) (Shavers et al, 2004). One of the
major limitations of this study is that the patients included in the study had to be eligible for
Medicare (age 65 years of age and older). AA men are twice as likely to be diagnosed with
PrCa before the age of 50. The strengths of this study were that the authors were able to
evaluate the presence or absence of co-morbidities using the claims data from Medicare and
they were able to adjust for education and income status. Similarly, Mettlin and colleagues
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analyzed data from the National Cancer Data Base (NCDB) and it is consistent with other data
published by Polednak and Shavers in that AA men are more likely to receive no treatment
(29.1% versus 23.9%) and less likely to receive radiation therapy (28.5% versus 28.8%) and
radical prostatectomy (22.3% versus 29.1%) compared to Whites (Mettlin et al, 1997).
Cooperberg and colleagues examined 36 Urologic clinical sites across the U.S. and determined
that AA men were less likely to receive no treatment (6.2% versus 6.9%) and surgery (44.5%
versus 50.7%) while they were more likely to receive radiation (26.0% versus 24.8%)
(brachytherapy or external beam) (Cooperberg et al, 2010). The addition to this study that the
aforementioned studies did not evaluate is the receipt of cryosurgery. The results of the study
indicate that AA men were less likely to receive cryosurgery compared to White men
(Cooperberg et al, 2010). In 2009, Xiao and colleagues determined that NHW men diagnosed
with localized PrCa were more likely to receive brachy-monotherapy compared to AA men (Xiao
et al, 2009). In addition, Xiao and team evaluated an appropriate treatment group
categorization for PrCa patients using FCDS data and determined that treatment received was
significantly associated with race (p<0.0001), stage (p<0.0001), and age (p<0.0001) (Xiao et al,
2013). The recommended treatment categories were adapted in this study and discussed in
detail in Chapter 3. Table 6 compares the results of the studies on the receipt of no treatment,
radiation and surgery by race/ethnicity.
Table 6. Comparison of Results for Treatment Received by Race/Ethnicity

Treatment Modality

Study
Manuscript

Sample

Race/Ethnicity

No Treatment

Size
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Radiation

Surgery

Table 6 (Continued)

Polednak and

4,621

Flannery, 1992
(Conn State CR)

AA versus W

Localized

Localized

Localized

(5.69%

9.8% vs 10.2%

15.8% vs

6.8% vs 10.8%

AA)

p-value=0.986

13.5%

p-value=0.182

p-value=0.541
Mettlin et al,

251,416

1997

(9.95%

(ACoS, NCDB)

AA)

Shavers et al,

24,974

2004

(10% AA)

AA versus W

AA versus W

29.1% vs 23.9%

28.5% vs

22.3% vs

28.8%

29.1%

NA

NA

Localized and

Localized and

Localized and

Regional

Regional

Regional

NA

(external

30.6% vs

beam)

35.4%

Adjusted OR =
1.3, 95% CI (1.2,
1.6)

(SEERMedicare)
Underwood et

142,340

AA versus W

al, 2004 (SEER)

26.5% vs
23.9%
Xiao et al, 2009

104,050

AA versus W

(9.4% AA)

Cooperberg et

11,892

al, 2010

(10.35%

(CaPSURE,

AA)

AA versus W

Localized

Localized

Localized

12.8% vs 10.8%

25.3% vs

33.3% vs

26.6%

32.7%

26.0% vs

44.5% vs

24.75%

50.7%

6.2% vs 6.9%

40 urology
practices)
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Table 6 (Continued)
Xiao et al, 2013

60,497

(FCDS)

AA versus W

No definitive tx

20.69% vs

40.57% vs

(11.9%

14.94% vs

23.77%

40.61%

AA)

13.09%

AA = African American
W = White

Mettlin and colleagues state that “race related variations in PrCa treatment patterns are
poorly understood” (Mettlin et al, 1997). In addition, AA men represent a high risk population
disproportionately affected by this preventable disease and there is very little known about PrCa
and treatment patterns among AA men in the State of Florida. Hence, this study focused on
examining the race/ethnic differences in PrCa treatment patterns among newly diagnosed men
in Florida diagnosed with PrCa.
Diet and Obesity
Pienta and Esper determined, after an analysis of the literature and SEER data, that the
most dominant PrCa risk factor is dietary fat (Pienta and Esper, 1993). In addition, using data
from the prospective cohort of participants in the Health Professionals Follow-up Study,
Giovannucci and colleagues examined the association between the consumption of dietary fat
and advanced stage PrCa and concluded that men who had a high consumption of red meat
had a significant 3 fold increased risk of developing advanced stage PrCa compared to those
with low consumption of red meat (Giovannucci, 1993). Rodriguez and colleagues evaluated
the consumption of red meat among AA and White men in the Cancer Prevention Study II
(Rodriguez et al, 2006). The results of the study indicate that AA men were more likely to
consume more poultry and processed meat (bacon, hot dogs and sausage) and less likely to
consume unprocessed meat compared to White men (Rodriguez et al, 2006). Consumption of
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processed red meat was significantly associated with a higher incidence of PrCa among the AA
men, RR=2.7; 95%CI (1.3-5.3) compared to White men (Rodriguez et al, 2006). Similarly,
Whittemore and colleagues conducted a case control study among men in the US and Canada
and determined that the total fat intake was significantly associated with an increased risk of
developing PrCa among AA, White and Asian men (Whittemore, 1995). On the other hand,
Cohen and colleagues found that a high consumption of fruits and vegetables significantly
reduced the risk of developing PrCa in a case control study among men less than 65 years of
age (Cohen et al, 2000). In contrast, Mills and team did not find any significant association
between the consumption of animal meat and PrCa after adjusting for the consumption of fruits
and vegetables (Mills et al, 1989); however, it is important to note that the study population
consisted of males in the Seventh-Day Adventist denomination and consumption of pork is not
recommended and considered a dietary restriction (Mills et al, 1989). In addition, Hsing
conducted a prospective cohort study among males of the Lutheran Brotherhood Insurance
Society and determined that there was no association between meat, dairy consumption or
vegetables and PrCa (Hsing et al, 1990). Severson and colleagues conducted a study among
Japanese men and their risk of PrCa along with dietary practices utilizing a food frequency
questionnaire (Severson, 1989). The results of the study indicate that there was a significant
increased risk of developing PrCa among those who consumed bread 2 to 4 times per week (3fold increased risk), eggs 2 to 4 times per week (2-fold increase risk) and seaweed 5 or more
times per week (2-fold increased risk) (Severson, 1989).
In a double blind cancer prevention trial that included approximately 1,000 men who
were randomized to consume the dietary supplement selenium (Se) or a placebo, the results of
the study indicate that the incidence of PrCa was significantly lower in the Se group compared
to the placebo group, Relative Risk (RR) = 0.37, p=0.002 (Clark, 1998). Approximately 1,900
men from the Physicians’ Health Study were evaluated in a nested case control study to
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examine the risk of PrCa and lycopene levels (Gann, 1999). The authors concluded that the
consumption of lycopenes reduced the risk of developing PrCa and provided several reasons
why this is biologically plausible (Gann, 1999).
Murphy and colleagues evaluated the association of vitamin D deficiency and prostate
cancer among ~700 AA and White men in Chicago (Murphy et al, 2014). The results of the
study indicate that vitamin D deficiency may be used to predict aggressive or advanced prostate
cancer versus prostate cancer diagnosis because the authors collected the serum to measure
the vitamin D at the time near the first prostate biopsy (Murphy et al, 2014). AA men comprised
41% of the study population and they were less likely to have a negative initial prostate biopsy
compared to White men, 37% versus 41%, respectively (Murphy et al, 2014). Additional studies
are needed in this area, especially to compare men in southern states to men in northern states
since vitamin D is derived from sunlight.
Regarding obesity, Snowdon and colleagues conducted a study on diet, obesity and
PrCa among Seventh-Day Adventist men and determined that the risk of PrCa increased 2-fold
among those who were overweight and a 4 fold increase risk of developing PrCa was obtained
among those who consumed animal products (Snowdon, 1984). A primary limitation of this
study is that the study only included white males, so the results were not generalizable to men
in other race/ethnic groups.
In summary, diet and obesity are modifiable risk factors and the current literature
examining the association between PrCa and diet is not consistent and further evaluation is
needed, especially among diverse populations.
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Tobacco and Alcohol
Hiatt and colleagues determined that smoking ≥1 pack of cigarettes/day was significantly
associated with an increased risk of PrCa among members of a healthcare plan in California,
adjusted RR = 1.9, 95%CI (1.2, 3.1). Hsing and team evaluated tobacco use among the
Lutheran Brotherhood Cohort and concluded that men who ever used cigarettes, RR = 1.8,
95%CI (1.1, 2.9) or ever used smokeless tobacco, RR = 2.1, 95%CI (1.1,4.1) had a significant
increased risk of developing PrCa (Hsing et al, 1990).
Dennis conducted a meta-analysis of 33 cohort and case control studies and concluded
that there was no association between PrCa and alcohol or beer consumption (Dennis, 2000).
Similarly, Hiatt and team found no association between alcohol consumption and risk of PrCa
among men in California among members of a healthcare plan (Hiatt et al, 1994). On the other
hand, Jain and colleagues evaluated alcohol, beer, wine, coffee and liquor consumption among
Canadian men in a case control study and determined that 10 or more beers consumed per
day, OR=0.68, 95%CI (0.49,0.94) or consuming 1-9 glasses of wine per day, OR=0.77, 95%CI
(0.60-0.99) both had a significant protective association with PrCa while there was no significant
association with alcohol or any of the other beverages (Jain et al, 1998). Hayes and colleagues
evaluated the association of alcohol consumption and PrCa among AA and White men in a
multi-center case control study and concluded that AA men who were heavy alcohol drinkers
(consumed ≥57 drinks/week) had a 2 fold significant increased risk of having PrCa compared to
never drinkers, OR=1.8, 95%CI(1.1,3.0) (Hayes et al, 1996). This same trend was observed in
White men (Hayes et al, 1996).
Like diet and obesity, tobacco use is a modifiable risk factor that has the potential of
increasing the risk of PrCa. The literature does not consistently show a positive relationship
between PrCa and alcohol use. Alcohol, beer and the consumption of other beverages are
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modifiable risk factors that need further investigation especially among high risk populations
affected by PrCa. In addition, studies focusing on the psychosocial aspects of why alcohol
consumption is elevated or not among the high risk population will add an additional layer of
knowledge surrounding the association of alcohol and PrCa risk.
Socioeconomic status
Bennett and colleagues evaluated 212 men with low income status using the Rapid
Estimate of Adult Literacy in Medicine (REALM) reading screening test and it was determined
that AA men with a low income status were more likely to have a less than 6th grade reading
level (Bennett et al, 1998). Even after adjusting for reading level, geographic U.S. location, and
age, race was not significantly associated with low income men having advanced PrCa. The
results of this study indicate that income and reading level are not associated with AA men
having an increased risk of developing PrCa. The primary limitation of this study is the low
number of AA men included in the study (n=109). Similarly, the study conducted by Ward and
colleagues indicate that American Indian/Alaska Native and AAs have a higher percentage with
income below the poverty level, 27% and 24%, respectively, compared to Non-Hispanic Whites
with 8% (Ward et al, 2004). In addition, 31% and 17% of Hispanics and AAs, respectively, have
no regular source of medical care compared to 14% of Non-Hispanic Whites (Ward et al, 2004).
The highest percentage of those under 65 years of age with no healthcare coverage was seen
among Hispanics, 35%, and American Indian/Alaska Native, 33% (Ward et al, 2004).
Roetzheim and team determined that insurance status and race are associated with
PrCa stage at diagnosis (Roetzheim, 1999) where AA men who had non-private insurance or
those who did not have any insurance were more likely to be diagnosed with advanced stage
cancer (Roetzheim, 1999). The lack of health insurance has been described as being a
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‘structural barrier’ in the ability of AA men seeking appropriate early detection and cancer
treatment (Ward et al, 2004).
More research is needed, especially among studies with an adequate representation of
AA men, in the area of socioeconomic status and the risk of PrCa because the literature does
not consistently show the same relationship between PrCa risk as it relate to education, health
insurance status and race.
Vasectomy
Giovannucci conducted a cohort study among men 40-75 years of age, enrolled on the
Health Professional Follow-up Study who were cancer free and had a vasectomy (Giovannucci,
1999). The results of the study indicate that men with a vasectomy had a statistically significant
increased risk of developing PrCa compared to men without a vasectomy, age-adjusted relative
risk (AARR) = 1.66, p-value =0.0004 (Giovannucci, 1999). In addition, the AARR of developing
PrCa significantly increased as the time from the date of the vasectomy increased (Giovannucci,
1999). On the other hand, Cox and colleagues found no statistically significant increased risk of
developing PrCa after a vasectomy in a case control study (Cox, 2002). Based on the current
literature there is no consensus on the risk of developing PrCa after a vasectomy and additional
research is needed in order to understand this association.
Prostatitis
Sarma and team conducted a case control study to evaluate the risk of PrCa and
prostatitis and concluded that AA men who reported having prostatitis had a 5 fold significant
increased risk of having PrCa, adjusted OR = 4.93, 95%CI (2.79-8.74) (Sarma et al, 2006). In
addition, a meta-analysis was conducted by Dennis and team and the results of the study
concluded that men with a history of prostatitis had significant increased odds of having PrCa
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(Dennis et al, 2002). Furthermore, Nelson and team indicated that inflammation of the prostate
gland is a precursor and initiates the carcinogenic process (Nelson et al, 2004). Likewise,
Roberts and team conducted a matched case control study among Minnesota residents and
concluded that cases with a confirmed history of acute prostatitis were significantly more likely
to be diagnosed with PrCa compared to the controls, OR=2.5, 95% CI (1.3-4.7) (Roberts et al,
2004). The value added for this study is that the authors calculated the time from the last
episode of prostatitis diagnosis to the time of PrCa diagnosis and determined there was an
average of 12 years between this time; however, the time period was not statistically significant
(Roberts et al, 2004).
In summary, since prostatitis has been shown to increase the PSA level, Potts
recommend routine testing to determine the presence or absence of inflammation before
performing a biopsy (Potts, 2000). If there is evidence of inflammation, antibiotics are often
recommended followed by subsequent screening PSA tests (Potts, 2000). The biologic
plausibility or the role of pathogenesis for prostatitis increasing the PSA level is that the white
blood cell count is higher than normal due to the presence of inflammation inside the body
(Neal, 1992).
Sexually Transmitted Infections (STI)
Taylor and colleagues completed a meta-analysis and concluded that men with a history
of any sexually transmitted disease/infection have a statistically significant increased risk of
developing PrCa, OR=1.48, 95% CI (1.26, 1.73) (Taylor et al, 2005). The sexually transmitted
infections are applicable to gonorrhea, syphilis, chlamydia, herpes and human papilloma virus
(HPV). Hayes and team evaluated the same aforementioned STIs in a case control study;
however, AA men were included in the study representing 51% of the men interviewed (Hayes
et al, 2000). AA men were more likely than White men to report a history of having a STI and
the risk of PrCa was significantly increased when men reported a history of having both syphilis
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and gonorrhea (Hayes et al, 2000). In addition, AA men who reported having 3 or more
occurrences of gonorrhea had a 3 fold increased risk of having PrCa compared to those who
never had gonorrhea, OR=3.5, 95%CI (1.4-8.3) (Hayes et al, 2000). Likewise, Sarma and
colleagues had similar results from a case control study, where AA men who reported having a
history of gonorrhea having a significant increased risk of PrCa, after adjusting for various
potential confounders, adjusted OR=1.78, 95%CI (1.13-2.79) (Sarma et al, 2006). A study
conducted among men in Cuba yielded similar results. Cuban men with a history of a STI had a
significant increased risk of having PrCa, OR=1.7, 95%CI (1.1, 2.5) (Fernandez et al, 2005).
In summary, the literature shows that men with a personal history of having a STI have
an increased risk of developing PrCa. The biologic plausibility of this association is due to the
STI leading to prostatitis or inflammation of the prostate and the inflammation initiating
carcinogenesis (Taylor et al, 2005).
Occupation
Krstev and colleagues conducted a case control study to evaluate the risk of PrCa and
occupation/industry using death certificates and determined that men in both blue collar and
white collar occupations had an excess risk of PrCa (Krstev, 1998). In addition to evaluating
occupation, Hsing and colleagues evaluated physical activity among newly diagnosed PrCa
cases reported to the Cancer Registry in urban Shanghai and concluded that men in
occupations associated with obtaining less physical activity have a higher risk of developing
PrCa (Hsing et al, 1994). It is important to note that the association was not statistically
significant.
Among men living in Hawaii with Japanese ancestry, Severson and team, conducted a
case control study and compared to men in an unskilled manual occupation, men in a skilled
manual occupation had an increased risk of PrCa, RR=1.30, 95%CI (0.83, 2.03) and men in
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non-manual (managerial) occupations had an increased risk of PrCa, RR=1.24, 95%CI (0.78,
1.95); however, none of the RRs were statistically significant (Severson et al, 1989). Similarly, a
case control study conducted among Italian men concluded that clerical and professional
workers had an increased risk of PrCa compared to industry or manual workers , adjusted RR =
1.53, 95%CI (0.83-2.83); however, the association was not statistically significant (Talamini et
al, 1986). On the other hand, a case control study evaluating occupation, industry and cancer
among Canadian men resulted in statistically significant associations between the risk of PrCa
and water transport workers, railway transport workers, structural erectors, metal product
fabricators and aircraft manufacturing occupations/industries (Aronson et al, 1996).
In summary, the literature is showing an overall positive association between
occupation/industry and the risk of developing PrCa; however, very few occupation/industry
associations have been shown to be statistically significant (Aronson et al, 1996; Talamini et al,
1986; Severson et al, 1989). One of the primary limitations of the literature evaluating
occupation/industry and the risk of PrCa is a low representation of AA men in the study groups
which makes it difficult to extrapolate any information specific to this high risk group of men.
Summary of PrCa Risk Factors
It is clear that more research is needed in the area of PrCa etiology. Out of all the
aforementioned risk factors, Lichtenstein and colleagues indicate that having a family history of
PrCa explains 40% of PrCa disease risk (Lichtenstein, Holm, et al, 2000). In terms of modifiable
risk factors it is important the men focus on the risk factors they can control such as diet,
exercise, exposure to sexually transmitted infections, tobacco smoking and alcohol
consumption.
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Background information on the National Comprehensive Cancer Network (NCCN)
The vision of NCCN is to “be the world’s leader in defining and advancing high quality,
high volume cancer care” (www. NCCN.org, 2012 Annual Report). NCCN is a not for profit
organization of 25 cancer centers across the U.S. that was created in November 1993 to
implement standards of cancer care (www.NCCN.org). Moffitt Cancer Center and Research
Institute is the only NCCN member institution in the State of Florida. The complete list of all 25
NCCN cancer centers is provided in Table 7 below.
Table 7. NCCN Participating Cancer Centers
NCCN Cancer Center
City of Hope Comprehensive Cancer
Center
Dana Farber/Brigham and Women’s
Cancer Center, Massachusetts
General Hospital Cancer Center
Duke Cancer Institute
Fox Chase Cancer Center
Huntsman Cancer Institute at the
University of Utah
Fred Hutchinson Cancer Research
Center/Seattle Cancer Care Alliance
The Sidney Kimmel Comprehensive
Cancer Center at Johns Hopkins
Robert H. Lurie Comprehensive
Cancer Center of Northwestern
University
Memorial Sloan-Kettering Cancer
Center
Moffitt Cancer Center
The Ohio State University
Comprehensive Cancer Center James Cancer Hospital and Solove
Research Institute
Roswell Park Cancer Institute
Siteman Cancer Center at BarnesJewish Hospital and Washington
University School of Medicine
St. Jude Children’s Research
Hospital/The University of
Tennessee Health Science Center
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Location
Los Angeles, California
Boston, Massachusetts
Durham, North Carolina
Philadelphia, Pennsylvania
Salt Lake City, Utah
Seattle, Washington
Baltimore, Maryland

Chicago, Illinois
New York, New York
Tampa, Florida

Columbus, Ohio
Buffalo, New York

St. Louis, Missouri

Memphis, Tennessee

Table 7 (Continued)
Stanford Cancer Institute
University of Alabama at Birmingham
Comprehensive Cancer Center
UCSF Helen Diller Family
Comprehensive Cancer Center
University of Michigan
Comprehensive Cancer Center
Fred and Pamela Buffett Cancer
Center at The Nebraska Medical
Center
Yale Cancer Center/Smilow Cancer
Hospital

Mayo Clinic Cancer Center
UC San Diego Moores Cancer
Center
University of Colorado Cancer
Center
The University of Texas MD
Anderson Cancer Center
Vanderbilt-Ingram Cancer Center

Stanford, California
Birmingham, Alabama
San Francisco, California
Ann Arbor, Michigan

Omaha, Nebraska
New Haven, Connecticut
Phoenix/Scottsdale,
Arizona
Jacksonville, Florida
Rochester, Minnesota
La Jolla, California
Aurora, Colorado
Houston, Texas
Nashville, Tennessee

Source: www.NCCN.org
In November 1996, the first NCCN Clinical Practice Guidelines in Oncology were created
and PrCa was included as one of seven cancer sites released with clinical evidence based
practice guidelines for clinicians to utilize (www.NCCN.org, 2012 Annual Report). Since the
first Clinical Practice Guidelines in Oncology were released over 17 years ago,
updates/changes have been made in order to provide clinicians and patients with
comprehensive decision-making educational material (www.NCCN.org, 2012 Annual Report).
As of 2013, the NCCN has created over 50 Clinical Practice Guidelines in Oncology, created
over 140 algorithms and all of the member cancer centers see ~160,000 new patients per year
(www.NCCN.org). The NCCN Clinical Practice Guidelines continuously update evidence
based clinical recommendations for decisions made in cancer screening, diagnosis and
treatment (www.NCCN.org, 2012 Annual Report). The standard of care for patients diagnosed
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with PrCa, based on NCCN guidelines, depend on various factors such as life expectancy,
clinical stage, Gleason score (Gleason primary and secondary pattern), the results of bone
scan, magnetic resonance imaging (MRI) and/or pelvic computed tomography (CT) scan, risk of
recurrence and expected survival (NCCN Prostate Guidelines v4.2013).
The primary advantage of utilizing the Clinical Practice Guidelines created by the NCCN
is that the recommendations are evidence based (www.NCCN.org, 2012 Annual Report). The
primary limitation of using the Clinical Practice Guidelines created by the NCCN is that clinicians
are not required to follow the recommendations; therefore, there may be variation in the way the
recommendations are implemented in clinical practice. Secondly, the NCCN recommendations
are not personalized and may not be applicable to all patients. For example, 5% of the PrCa
tumors have a rare histology (Bostwick et al, 1989) and the NCCN clinical treatment guidelines
target patients diagnosed in the 95% histology group.
Background Information on the Florida Cancer Data System (FCDS)
FCDS was created in 1978 based on a Florida Legislature mandate to create a state
cancer registry and by 1980 the University of Miami started a pilot study to collect data on
approximately 5,000 cases from Southeast Florida (Dr. Jill MacKinnon presentation at FCDS
annual conference on 7/25/13). In early 1980, a total of six hospitals reported cancer cases to
FCDS and the State of Florida and by the middle of 1981 approximately 1,500 cancer cases
were reported to FCDS (Dr. Jill MacKinnon presentation at FCDS annual conference on
7/25/13). As of July 25, 2013, 244 hospitals, 136 radiation treatment centers, 429 surgery
centers, 661 pathology centers and 1,334 private physician offices are currently reporting cases
to FCDS (Dr. Jill MacKinnon presentation at FCDS annual conference on 7/25/13). Newly
added in 2012, private physicians that work in the specialty areas of Dermatology, Oncology,
Urology and Hematology started reporting their cancer cases to FCDS (Dr. Jill MacKinnon
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presentation at FCDS annual conference on 7/25/13). With the additional cases being reported,
the number of yearly FCDS cases is expected to increase over 20% in order to fill the gap with
cases that have been considered to be underestimated (Dr. Jill MacKinnon presentation at
FCDS annual conference on 7/25/13). For example, in a pilot study conducted by FCDS it was
determined that 29% of the cases were missed because physician offices do not report
diagnosis and treatment to FCDS (Dr. Jill MacKinnon presentation at FCDS annual conference
on 7/25/13). More specifically, it was determined that 15% of the missed cases were
leukemia/lymphoma cases, 11% of the missed cases were early stage gynecologic and prostate
cases and 10% were myleodysplastic syndrome (MDS) cases (Dr. Jill MacKinnon presentation
at FCDS annual conference on 7/25/13).

In June 2012, FCDS started collecting diagnosis and

treatment information from physician offices such as Florida Cancer Specialists that include
approximately 150 physicians in 30 counties across the State of Florida utilizing claims data with
Current Procedural Terminology (CPT), Healthcare Common Procedure Coding System
(HCPCS) and the International Classification of Diseases, ninth revision (ICD-9) codes to
identify the cancer diagnoses corresponding to the procedures (Dr. Jill MacKinnon presentation
at FCDS annual conference on 7/25/13). As a result of the pilot study an additional 3.7 million
additional rows of data were added with a 71% match rate at the patient to tumor level (Dr. Jill
MacKinnon presentation at FCDS annual conference on 7/25/13). The impact of this limitation
with the FCDS data on the current study is that this study is not generalizable to patients who
are diagnosed and treated in State of Florida in a physician’s office.
The data collected by FCDS is abstracted at the hospital/facility level by Certified Tumor
Registrars (CTR) and non-CTRs (Michael Thiry presentation at FCDS conference on 7/25/13).
As of July 2013, there are 461 abstractors with a valid FCDS abstractor code (Michael Thiry
presentation at FCDS conference on 7/25/13). Over 190,000 cancer abstracts and
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approximately 900,000 pathology records were submitted during FY 2013 (July 1st – June 30th)
(Michael Thiry presentation at FCDS conference on 7/25/13).
The quality of the FCDS data is evaluated on a quarterly and annual basis at the local
Cancer Registry hospital level and by FCDS. At the national level, FCDS has been awarded
Silver and Gold level certification by the North American Association of Central Cancer
Registries (NAACCR) for the quality, completeness and timeliness of data that has been
submitted indicating that FCDS has consistently achieved 90% or higher complete case
ascertainment (NAACCR website on 8/14/13, http://www.naaccr.org/Certification/Criteria.aspx).
FCDS has successfully maintained complete case ascertainment of 95% or higher since 1998
(NAACCR website on 8/14/13, http://www.naaccr.org/Certification/Criteria.aspx). Certification
by NAACCR is important because the certification establishes that the data is high quality and
can be utilized for the purpose of calculating incidence rates (NAACCR website on
8/14/13, http://www.naaccr.org/Certification/Criteria.aspx). For the past 11 years, data
representing CY2000 through CY2010, FCDS has consecutively received the NAACCR Gold
Certification indicating the highest possible NAACCR standard for complete, timely and
accurate data (see Table 8) (NAACCR website on
8/14/13, http://www.naaccr.org/Certification/Criteria.aspx).

Table 8. FCDS NAACCR Certification Levels by Calendar Year
Calendar Year

Gold

Silver

1997

Certified
X

1998

X

1999

X
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2000
Table 8 (Continued)
2001

X

X

2002

X

2003

X

2004

X

2005

X

2006

X

2007

X

2008

X

2009

X

2010

X

In terms of responsibility for the quality of the FCDS data, the hospitals/facilities who
submit the data have multiple data edits that must be satisfied before the abstracted data can
be electronically submitted to FCDS. The data edits serve as the first pass in terms of verifying
the quality of the data. Additional quality checks are completed by FCDS staff once the
hospital/facility data is submitted to FCDS. If there are any questions about a case after it is
submitted, FCDS contacts the respective facility/hospital, as needed, for additional clarification
and/or documentation.
At the hospital/facility level, the treatment data is coded according to the primary site of
treatment. For example, if a patient is diagnosed with primary PrCa the primary site of surgery
can be a radical or total prostatectomy. In addition to the type of treatment that is administered,
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the treatment start date and treatment end date are also collected. The treatment end dates
may be unknown for some treatment modalities, especially for patients that are undergoing
hormone, chemotherapy or immunotherapy at the time the case was abstracted. When FCDS
receives the data the first course of treatment modalities can be dichotomized into treatment
modality administered equal yes or treatment modality administered equal no (example: first
course surgery = yes or first course surgery = no). The same is true for the other first course of
treatment modalities such as chemotherapy, radiotherapy, hormone therapy and
immunotherapy.
There are changes to the data elements collected over time by FCDS. Most of this is
due in part to the changes in how the Cancer Registry data is collected and coded at the
national level. For example, Collaborative Staging (CS), a cancer staging guideline system,
was implemented in 2004 and applies to cases that were diagnosed on or after January 1, 2004
(cancerstating.org, 2014). The CS system will no longer be used starting in 2016 and the
American Joint Committee on Cancer will continue to be used in place of CS
(cancerstaging.org, 2014). In addition, as the knowledge of cancer and treatment options have
enhanced over the years so has the possibilities and available options in coding and
documenting the cancer occurrences along with the variety of data elements collected that can
be analyzed in order to better understand the cancer process. For this study, the time period in
which there were minimal data element changes, from a clinical perspective, was evaluated.
The data elements selected and the rationale for selecting the data elements are discussed in
Chapter 3.
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CHAPTER THREE: METHODOLOGY
Study Design

The overall goal of this study was to examine the differences in treatment/management
strategies that were newly diagnosed AA and NHW men in Florida newly diagnosed with
pathologically-confirmed PrCa. This study utilized retrospective data collected from cancer
registries and facilities in the State of Florida and the study design is a retrospective cohort
study. A major strength of this study design, which utilized cancer registry data, was that the
data were collected by trained staff using a standardized format.
Study Population
The proposed study population consisted of incident PrCa cases that were diagnosed in
Florida or elsewhere and received all or part of their first course treatment in Florida. Diagnosis
of PrCa was defined using the C61.9 International Classification of Diseases for Oncology, Third
Edition (ICDO-3) code (Fritz et al, 2000). The treatment modalities of interest include no
treatment, surgery, radiation, hormone therapy, immunotherapy and chemotherapy. NH AA and
NHW men were included in this study analyses.

Data Sources
This study utilized publicly available data from the FCDS cancer which includes PrCa
cases from 1982-2012, see Appendix D. The Florida Department of Health (FL DOH) and
FCDS are responsible for maintaining the publicly available cancer registry data collected
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throughout the State of Florida. FCDS is supported by the Sylvester Comprehensive Cancer
Center at the University of Miami Miller School of Medicine, the FDOH and the National
Program of Cancer Registries (NPCR) of the Centers for Disease Control and Prevention
(CDC).
Statistical Analysis Products
The Statistical Analysis Software (SAS) version 9 (SAS Institute, Inc., Cary, NC) and Microsoft
Excel version 2010 were utilized to perform all analyses.

Inclusion/Exclusion Criteria
Appendix C details the inclusion/exclusion criteria for the variables of interest included in this
study and Appendix D detailed the list of variables available for request from FCDS. The final
inclusion/exclusion criteria are described in detailed in Appendix M. The rationale for including
the data elements identified in the inclusion/exclusion criteria were as follows:
•

Primary site used was C61.9 from the International Classification for Diseases,
Oncology, Third Edition (ICDO-3) which represents PrCa.

Source: FCDS, Data Acquition Manual, 2013
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•

Morphology (histology) = adenocarcinoma was selected for analysis because
adenocarcinomas represent 95% of all PrCa tumors. The rare PrCa histologic types that
comprise 5% of PrCa cases, such as mucinous, ductal, neuroendocrine and small cell
carcinoma was not addressed (Bostwick et al, 1989).

•

Class of case
o

Class of case determines newly diagnosed cases (analytic) versus cases that
present to a facility with recurrent, progressive or persistent disease (nonanalytic). The cases of interest in this study were the newly diagnosed (analytic)
cases. The analytic cases represent class of case equal to 00 – 22.

48

49

Source: FCDS, Data Acquition Manual, 2013
•

Master sequence number = 00 or 01
o

Sequence number determines the number of multiple primary tumors a patient
has. The PrCa tumors of interest for this study were the tumors where PrCa was
the only primary cancer or PrCa was the first of many primary cancers, based on
FCDS records.
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Source: FCDS, Data Acquition Manual, 2013
•

Diagnostic confirmation was determined by selecting cases that had pathologically
confirmed primary prostate adenocarcinoma cancer.
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Source: FCDS, Data Acquition Manual, 2013
•

Cases with age at diagnosis greater than or equal to 18 years of age were included in
this study.

•

The study population was limited to race equal to AA (Black) or White.
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Source: FCDS, Data Acquition Manual, 2013
•

The study population was limited to Spanish/Hispanic Origin equal to Non-Hispanic only.
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Source: FCDS, Data Acquition Manual, 2013
•

Behavior
o

Confirmed that prostate tumor is malignant in order to exclude any benign
tumors.
Study Variables

•

Life expectancy, a derived or calculated variable using the Social Security Administration
Life Table (see Appendix F).

54

o

Life expectancy was the variable of interest and not years of potential life lost in
order to effectively compare the NCCN Clinical Practice Guidelines over time.

•

Treatment modalities
o

Surgery Date

Source: FCDS, Data Acquition Manual, 2013
o

Surgery of primary site
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Source: FCDS, Data Acquition Manual, 2013
o

Surgery procedure

Source: FCDS, Data Acquition Manual, 2013
o

Reason for no surgery
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Source: FCDS, Data Acquition Manual, 2013
o

Chemotherapy
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Source: FCDS, Data Acquition Manual, 2013

o

Chemotherapy date

Source: FCDS, Data Acquition Manual, 2013
o

Hormone or Endocrine therapy
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Source: FCDS, Data Acquition Manual, 2013

Source: FCDS, Data Acquition Manual, 2013
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o

Hormone Date

Source: FCDS, Data Acquition Manual, 2013
o

Radiation Date

Source: FCDS, Data Acquition Manual, 2013
o

Radiation Therapy
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Source: FCDS, Data Acquition Manual, 2013
o

Immunotherapy Date

Source: FCDS, Data Acquition Manual, 2013
o

Immunotherapy
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Source: FCDS, Data Acquition Manual, 2013
•

Date of last contact or Date of death
o

FCDS passively receives date of death from the National Death Index and the
Florida Department of Vital Statistics.

Source: FCDS, Data Acquition Manual, 2013
•

Vital status (dead/alive)
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Source: FCDS, Data Acquition Manual, 2013
•

Tobacco use

Source: FCDS, Data Acquition Manual, 2013
•

Marital status
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Source: FCDS, Data Acquition Manual, 2013
•

Primary Payer at Diagnosis
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Source: FCDS, Data Acquition Manual, 2013
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•

Date of diagnosis

Source: FCDS, Data Acquition Manual, 2013
•

Cancer status (no evidence of disease versus evidence of disease versus unknown)
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Source: FCDS, Data Acquition Manual, 2013
•

Grade/Differentiation
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Source: FCDS, Data Acquition Manual, 2013
•

County of residence at diagnosis

•

SEER Summary Stage (1997 and 2000) (local versus regional versus distant disease)

•

Collaborative Staging site specific factor 1, PSA lab value (document the highest prebiopsy or pre-surg PSA value)

•

Collaborative staging site specific factor 2, PSA lab value category (positive, negative,
borderline, test not done, unknown)

•

Collaborative staging site specific factor 5 (Gleason’s pattern)

•

Collaborative staging site specific factor 6 (Gleason’s score)

•

Collaborative staging lymph nodes

Xiao and colleagues created a treatment categorization methodology for PrCa first course of
treatment modalities in order to achieve an adequate sample size as well as treatment groups
that are clinically relevant (Xiao et al, 2013). Using FCDS data, the team had a total of 14
different treatment categories that were truncated to 8 categories that were mutually exclusive
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(Xiao et al, 2013). The following 10 treatment categories was adapted from the study by Xiao
and team and utilized in this study (Xiao et al, 2013):
•

Surgery only

•

Surgery + radiation therapy

•

Surgery + radiation therapy + hormone therapy

•

Surgery + hormone therapy

•

Hormone therapy

•

Radiation therapy

•

Radiation therapy + hormone therapy

•

Other therapy (chemotherapy and/or immunotherapy with surgery)

•

No treatment (watchful waiting = no surgery, hormone therapy, radiation therapy or
other therapy received within the first 6 months after the month of diagnosis)

•

Active Surveillance (active surveillance = no surgery, hormone therapy radiation
therapy or other therapy received with the first year after the month of diagnosis,
starting from 6 months and 1 day so that the time for active surveillance does not
overlap with the time period for no treatment/watchful waiting)

Statistical Methodology
Preliminary Analyses
Based on the aggregate, de-identified data obtained from FCDS in March 2013 there
were a total of 356,787 PrCa cases. The only exclusion made on the dataset was primary site
group = 51 (prostate). Tables 8, 9, and Appendix E, detail the demographic and clinical
characteristics of the PrCa cases. Utilizing previously described data elements from the FCDS,
the inclusion/exclusion criteria were applied to restrict to the cases of interest, which totaled
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227,799 PrCa cases (see Appendix F). Approximately 13% of the PrCa cases were NH AA
men while 87% were NHW men.
Hypothesis 1/Aim 1
Hypothesis 1
There are differences in the treatment patterns between AA men and NHW men newly
diagnosed with prostate cancer in Florida by stage at diagnosis/tumor grade and age at
diagnosis.
Aim 1
To compare the first course treatment modalities received by newly diagnosed prostate cancer
patients in Florida between AA and NHW men among men with the same stage at
diagnosis/tumor grade and age at diagnosis.
Chi-square tests of statistical independence or Fisher’s exact test was used to determine
the association between the categorical clinical and demographic variables of interest and
race/ethnicity, whereas the independent samples t-test was used to evaluate the association
between race/ethnicity and continuous variables. The p-values assessed were 2-sided. The
adjusted association between race/ethnicity and all of the variables was obtained by completing
a regression analysis. Multinominal logistic regression was used to compare the first course of
treatment modalities between AA and NHW men and to estimate adjusted odds ratio (AORs)
and 95% confidence interval (CI), which represent race/ethnicity-treatment association,
adjusting for the variables of demographic and clinical importance.
In the multinominal regression model, the dependent variable was treatment modality
(16 levels) and the primary independent variable was race/ethnicity. No treatment was used as
the comparison treatment group. Other independent variables were demographic (age at
diagnosis) and clinical variables (stage at diagnosis, tumor grade). The approach to model
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building was forward selection; however, there were study variables that were clinically
significant that were kept in the model even if they were not statistically significant.

Hypothesis 2/Aim 2
Hypothesis 2
The treatment modalities administered to AA men and NHW men newly diagnosed with PrCa in
FL may differ from recommended treatment as per NCCN guidelines among men with the same
stage at diagnosis/tumor grade, age at diagnosis and life expectancy.
Aim 2
To determine if the treatment modalities administered to AA men and NHW men differ from the
treatment recommendations of the NCCN among men with the same stage at diagnosis/tumor
grade, age at diagnosis and life expectancy.
In order to adequately compare the recommendations for the treatment modalities from
NCCN it was important to know the life expectancy of the PrCa patients. At the time of
diagnosis, life expectancy was extrapolated using the expectation of life table created by Arias
(Arias, 2010) and life expectancy was categorized into 3 groups, less than 10 years, between 10
and 19 years and greater than or equal to 20 years. The aforementioned life expectancy
categories were utilized because the NCCN guidelines were based on men that fall into those
categories. The treatment modalities adapted by Xiao and team was utilized in order to
determine adherence to the NCCN recommendations (Xiao et al, 2013). The treatment groups
were created by Xiao et al based on clinical relevance for patients diagnosed with PrCa and
having an adequate sample size.
One of the limitations noted with the methodology and study design is that men may die
from other disease related co-morbidities (competing risk), such as diabetes, hypertension or
73

heart disease and not PrCa or before the PrCa causes any detectable symptoms (Judy Bonner
and Mayra Espino presentation at FCDS annual conference on July 26, 2013). Secondly, once
the dataset is requested from FCDS it is a static dataset. If a patient died after the dataset was
released this information was not considered in this study.
The University of South Florida Institutional Review Board (USF IRB) approved this
study (IRB# Pro00016727). In addition, approval was also obtained from the Florida
Department of Health, Bureau of Epidemiology and FCDS to utilize the Limited CD with the
inclusion of vital status, date of last contact, date of last contact flag and passive follow-up date
of death data elements from the full confidential CD.
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CHAPTER FOUR: RESULTS
Part I. Hypothesis 1/Aim 1
Hypothesis 1
There are differences in the treatment patterns between AA men and NHW men newly
diagnosed with PrCa in Florida by stage at diagnosis/tumor grade and age at diagnosis.
Aim 1
To compare the first course treatment modalities received by newly diagnosed prostate cancer
patients in Florida between AA and NHW men among men with the same stage at
diagnosis/tumor grade and age at diagnosis.
Descriptive Statistics
The study population consisted of 244,449 NHW and AA men in Florida histologically
diagnosed with primary prostate cancer between calendar years 1982 to 2012. NHW men
represented 87.5% of the study population while AA men represented 12.5% of the study
population. Statistically significant race/ethnic differences exist by marital status (p<0.0001),
vital status (p<0.0001), year of diagnosis (p<0.0001), stage at diagnosis (p<0.0001), age at
diagnosis (p<0.0001), health insurance payer (p<0.0001), tumor grade (p<0.0001), no first
course treatment (p<0.0001), surgery only or surgery in combination with other treatment
modalities (p<0.0001), radiation therapy only (p<0.0001), surgery and radiation (p<0.0001),
hormone therapy or hormone therapy in combination with other treatment modalities
(p<0.0001), radiation and hormone therapy (p<0.0001), surgery/hormone/radiation therapy
(p=0.005), endocrine therapy only or endocrine therapy in combination with other treatment
modalities (p<0.0001) and other therapy (p<0.0001) (see Appendix N, Table 11). More
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specifically, AA men were more likely to be diagnosed with distant disease at diagnosis (8% vs.
5%), more likely to be diagnosed less than 50 years of age (4% vs. 1%, p<0.0001), more likely
to be diagnosed 50-64 years of age (41% vs. 25%, p<0.0001), more likely to have no health
insurance (3% vs. 1%, p<0.0001), more likely to have a higher tumor grade (grade 3, 36% vs.
30%, p<0.0001), more likely to have never been married (16% vs. 6%, p<0.0001) and more
likely to be alive (63% vs. 53%, p<0.0001) compared to NHW men.
Results by Stage at Diagnosis
Stratifying the results by race/ethnicity and stage at diagnosis, AA men were, on
average, consistently diagnosed with prostate cancer 4 years younger compared to NHW men
across all stages at diagnosis, localized disease (65 versus 69 years), regional disease (63
versus 67 years), and distant disease (69 versus 73 years) (See Appendix N, Table 12). In
addition, AA men have a wider age range at diagnosis (29-105 versus 32-104) compared to
NHW men. AA men were more likely to have never been married compared to NHW men with
AA men with distant disease having the highest percentage of those who have never been
married (20.38%). Regarding health insurance, AA men were more likely to have no health
insurance across all stages of disease compared to NHW men. On the other hand, NHW men
were more likely to be diagnosed with tumor grade 4 across all stages of disease compared to
AA men while AA men were more likely to be diagnosed with tumor grades 1, 2 and 3 across all
stages of disease compared to NHW men (See Appendix N, Table 12).
After adjusting for potential clinical and demographic confounders, the results by stage
at diagnosis indicate that AA men were significantly less likely to receive surgery only or surgery
in combination with other treatment modalities compared to NHW men. This result was
consistent across all stages of disease, localized (adjusted OR=0.66, 95% CI (0.63, 0.68),
p<0.0001), regional (adjusted OR=0.63, 95% CI (0.57, 0.71), p<0.0001) and distant (adjusted
OR=0.50, 95% CI (0.34, 0.75), p<0.0007) (See Appendix N, Table 13). Among men with distant
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disease one would expect them to receive chemotherapy, hormone therapy or immunotherapy
and the results of this study indicate that AA men with distant disease were significantly more
likely to receive other therapy which include chemotherapy only, immunotherapy only, endocrine
therapy only and other therapy only (adjusted OR=1.21, 95% CI (1.04, 1.40), p=0.01) compared
to NHW men. On the other hand, AA men with distant disease were less likely to receive
surgery in combination with other treatment modalities (adjusted OR=0.50, 95% CI (0.34, 0.75),
p<0.0007) or radiation and hormone therapy combined (adjusted OR=0.86, 95% CI (0.76, 0.98),
p=0.03) compared to NHW men. Appendix N, Table 14 summarizes the treatment patterns that
are statistically significant by stage at diagnosis.
Results for Treatment Modality
Regarding the receipt of treatment, AA men were less likely to receive no first course
treatment (23% vs. 29%, p<0.0001) or radiation therapy only (27% vs. 29%, p<0.0001)
compared to NHW men. AA men with localized or regional disease at diagnosis were more
likely to receive no first course treatment while there were no significant differences among AA
and NHW men with distant disease. In addition, AA men were more likely to receive hormone
therapy only for localized disease and less likely to receive hormone therapy only for distant
disease compared to NHW men. Although AA men were less likely to receive radiation therapy
only for regional disease there were no significant differences in the administration of radiation
therapy only among those with localized or distant disease compared to NHW men. For
treatment combination therapy, AA men were more likely to receive radiation and hormone
combination therapy for localized (16% vs 15%) or regional disease (10% vs 9%) compared to
NHW men.
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Results by Tumor Grade
There were no statistically significant differences in treatment for tumor grade 4 by
race/ethnicity (See Appendix N, Table 15). Similar to the results stratified by stage at diagnosis,
AA men were less likely to receive surgery compared to NHW men for tumor grade 1 (adjusted
OR=0.55, 95% CI (0.46, 0.67), p<0.0001), tumor grade 2 (adjusted OR=0.68, 95% CI (0.65,
0.71), p<0.0001) and tumor grade 3 (adjusted OR=0.57, 95% CI (0.53, 0.60), p<0.0001)
(Appendix N, Table 16). By tumor grade, AA men were more likely to receive hormone therapy
only or hormone therapy in combination with other treatment modalities compared to NHW men
for tumor grade 1 (adjusted OR=1.23, 95% CI (1.09, 1.38), p=0.0007), tumor grade 2 (adjusted
OR=1.22, 95% CI (1.17, 1.27), p<0.0001) and tumor grade 3 (adjusted OR=1.20, 95% CI (1.15,
1.26), p<0.0001). In addition, AA men were more likely to receive radiation only for tumor grade
1 and tumor grade 2; however, AA men were less likely to receive radiation therapy only for
tumor grade 3 (adjusted OR=0.94, 95% CI (0.90, 0.99), p=0.03). However, AA men with tumor
grade 3 were more likely to receive no first course treatment (adjusted OR=1.27, 95% CI (1.20,
1.35), p<0.0001). This contradicts previous research indicating that men diagnosed with
advanced prostate cancer were commonly administered hormone therapy, chemotherapy or
immunotherapy (Mettlin et al, 1997; Polednak and Flannery, 1992); Shavers et al, 2004;
Cooperberg et al, 2010; Albertsen et al, 1998).
Results by Age at Diagnosis
Evaluating age at diagnosis and treatment patterns stratified by race/ethnicity, AA men
across all age groups were less likely to receive surgery in combination with other treatment
modalities (age <50 (adjusted OR=0.71, 95% CI (0.61, 0.82), p<0.0001, age 50-64 (adjusted
OR=0.65, 95% CI (0.62,0.68), p<0.0001, age 65-74 (adjusted OR=0.62, 95% CI (0.58,0.65),
p<0.0001, age 75+ (adjusted OR= 0.56, 95% CI (0.44, 0.72), p<0.0001, compared to NHW men
(See Appendix N, Table 17 and Table 18). On the other hand, AA men were more likely to
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receive hormone therapy and/or radiation therapy in combination with other treatment modalities
across all age groups compared to NHW men. In addition, AA men age 50-64 (adjusted
OR=1.09, 95% CI (1.04-1.15), p=0.0012) and age 75+ (adjusted OR=1.19, 95% CI (1.11, 1.27),
p<0.0001) were more likely to receive no first course treatment compared to NHW men.
Summary of Hypothesis 1/Aim 1
Statistically significant race/ethnic differences exist by marital status, vital status, year of
diagnosis, stage at diagnosis, age at diagnosis, health insurance payer, tumor grade, no first
course treatment, surgery only or surgery in combination with other treatment modalities,
radiation therapy only, surgery and radiation, hormone therapy or hormone therapy in
combination with other treatment modalities, radiation and hormone therapy,
surgery/hormone/radiation therapy, endocrine therapy only or endocrine therapy in combination
with other treatment modalities and other therapy. Regarding age at diagnosis, AA men were
diagnosed with prostate cancer at an earlier age and have a wider age range compared to NHW
men.
The take home message for research question one is that regardless of age at
diagnosis, stage at diagnosis, or tumor grade, AA men were significantly less likely to receive
surgery only or surgery in combination with other treatment modalities compared to NHW men.
On the other hand, AA men were significantly more likely to receive radiation therapy only,
radiation therapy in combination with hormone therapy or hormone therapy only compared to
NHW men.
Reason for No Surgery
To better understand why AA men were less likely to receive surgery as part of first
course treatment compared to NHW men, the reason for no surgery variable was evaluated.
The overall reason for no surgery indicate that 49.4% of men received surgery as part of first
course treatment while 48.9% of men did not have surgery planned as part of first course of
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treatment (Figure 2 below). The remaining 1.7% of cases did not receive surgery as part of first
course of treatment because surgery was contraindicated, the patient died before surgery could
be performed, patient refused surgery, no reason given or surgery recommended but known if
performed.

Figure 2. Summary of the Reason for No Surgery
AA men were significantly more likely to not receive surgery as part of first course of
treatment compared to NHW men (52.8% versus 48.38%) and significantly more likely to refuse
surgery compared to NHW men (1.15% versus 0.74%) (Figure 3 below). There were also
statistically significant differences in the reason for no surgery by age at diagnosis, stage at
diagnosis and tumor grade (Figure 4 – Figure 6 below). Younger men, less than 65 years of
age, were more likely to have surgery as part of first course treatment while older men, 65 years
of age and older, were more likely to not receive surgery as part of planned first course of
treatment. Evaluating the reason for no surgery by stage at diagnosis indicate that men with
regional disease were more likely to receive surgery as part of first course of treatment while
men with localized and distant disease were more likely to not receive surgery as part of
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planned first course of treatment. On the other hand, men with tumor grades 1 and 4 were
more likely to receive surgery as part of first course of treatment and men with tumor grades 2
and 3 were more likely to not receive surgery as part of planned first course of treatment.
Further research is needed to better understand the decision making process on the physician
and patient side in terms of why surgery was not included as planned first course of treatment.

Figure 3. Reason for No Surgery by Race/Ethnicity
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Figure 4. Reason for No Surgery Stratified by Age at Diagnosis

Figure 5. Reason for No Surgery by Stage at Diagnosis
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Figure 6. Reason for No Surgery by Tumor Grade
Part II. Hypothesis 2/Aim 2
Hypothesis 2
The treatment modalities administered to African American men and Non-Hispanic White men
newly diagnosed with prostate cancer in FL may differ from recommended treatment as per
NCCN guidelines among men with the same stage at diagnosis/tumor grade, age at diagnosis
and life expectancy.
Aim 2
To determine if the treatment modalities administered to African American men and NonHispanic White men differ from the treatment recommendations of the NCCN among men with
the same stage at diagnosis/tumor grade, age at diagnosis and life expectancy.
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NCCN Initial Treatment Guidelines
The steps for evaluating the NCCN guidelines for initial treatment start with a prostate
cancer diagnosis followed by initial clinical assessment and staging workup and then a risk
group (very low, low, intermediate, high, very high, metastatic) is determined based on the
AJCC TNM T stage (Figure 7). Utilizing the AJCC TNM T staging along with patient life
expectancy the NCCN initial treatment recommendation is determined. The AJCC TNM staging
was created in order to estimate prognosis, examine trends in treatment, create a treatment
plan and to determine outcomes (AJCC, 6th edition).

Initial prostate cancer diagnosis

Initial clinical assessment

Staging workup
Determine risk group based on AJCC TNM T stage (very low, low, intermediate, high,
very high)
Expected life expectancy (<10 years versus ≥10 years)

NCCN intitial treatment recommendation

Figure 7. Process for Obtaining NCCN Initial Treatment Recommendation
The NCCN initial treatment recommendations over time have changed. For example,
the NCCN initial treatment recommendations are different for the very low risk group, low risk
group, intermediate risk group, high risk group and the very high risk group for the time periods
2004-2007, 2008-2009, 2010, and 2011-2012. The details of the NCCN initial treatment
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recommendation based on each of the aforementioned risk groups are described in detail in
Appendix B. The difference in the NCCN initial treatment recommendation from 2004-2007 and
2010 for the low risk group was that active surveillance only was added as the treatment
recommendation and radiation therapy was removed as a recommended treatment therapy. In
addition, the difference in the NCCN initial treatment recommendation from 2011-2012 changed
by including life expectancy, less than 20 years, with active surveillance being the initial
treatment recommendation and the TNM T stage changed from T1-T2a to include T1c only, with
the T1c group being defined as the very low risk group.
The major difference in the NCCN initial treatment recommendations for the intermediate
risk group was that hormone therapy was added in 2010 compared to 2004-2009 time period.
For the high risk group there were no changes in the NCCN initial treatment recommendations
over time. There was a change in the NCCN initial treatment recommendation for the very high
risk group where surgery was added as a treatment recommendation in 2008 and in 2010
radiation therapy with or without hormone therapy was added as an initial treatment
recommendation. This analysis focused on compliance of the NCCN initial treatment
recommendations from 2004-2009 because this time period include 6 years versus the other
time periods including 1 year and 2 years, respectively. There was consistency in the NCCN
treatment recommendations during this time period; therefore, allowing the clinician enough
time to implement a change in clinical practice.
AJCC TNM T Stage
In addition to the life expectancy variable, the American Joint Committee on Cancer
(AJCC) TNM stage variable was used to evaluate the NCCN recommended first course of
treatment. The FCDS dataset included AJCC TNM stage sixth edition which represent patients
diagnosed with prostate cancer between January 1, 2003 to December 31, 2009 and the AJCC
TNM seventh edition which represent patients diagnosed with prostate cancer on or after
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January 1, 2010 to current. The total number of prostate cancer cases diagnosed from calendar
year 2003 forward were 94,390 cases and the number of cases during the same time period
with AJCC 6th or 7th edition TNM T stage documented in the FCDS dataset was 85,694 cases
which indicate that 91% of the cases have TNM T stage coded so that the appropriate NCCN
treatment recommendations can be evaluated (Table 19). There were 8,696 (9%) of the cases
in 2003 with missing AJCC TNM T stage. Therefore, the study population for research question
2 was based on 85,694 cases. Per the AJCC TNM guidelines the T stage indicates the “extent
of the primary tumor or local tumor growth” (AJCC 6th Edition Staging Manual, 2002).
Table 19. Distribution of Prostate Cancer Cases by AJCC TNM T Stage, N=85,694

AJCC TNM T Stage

Count (%)

0

2 (0.002%)

T1a

714 (0.83%)

T1b

446 (0.52%)

T1c

36,431 (42.5%)

T1NOS

471 (0.55%)

T2a

9,251 (10.8%)

T2b

3,425 (4.00%)

T2c

19,512 (22.8%)

T2NOS

8,385 (9.8%)

T3a

3,384 (3.9%)

T3b
T3NOS

1,744 (2.04%)

T4

482 (0.56%)
1,039 (1.21%)
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Definition of AJCC
TNM T Stage*
There is no evidence of
a primary prostate
tumor
Tumor findings in 5%
or less of the tissue
Tumor findings in 5%
or less of the tissue
Tumor identified by
needle biopsy
T1 tumor, not
otherwise specified
Tumor comprises ½ of
1 lobe or less
Tumor comprises more
than ½ of 1 lobe but
not both lobes
Tumor comprises both
lobes
T2 tumor, not
otherwise specified
Tumor has unilateral or
bilateral extracapsular
extension
Tumor has invaded the
seminal vesicle(s)
T3 tumor, not
otherwise specified
Tumor has invaded

Table 19 (Continued)

Unknown
408 (0.48%)
Total
85,694
*Source: AJCC 6th and 7th edition staging manuals

other adjacent
structures other than
the seminal vesicle(s)
TNM T stage not
known

Life Expectancy Variable
In order to compare the treatment modalities administered and if the cases meet the
treatment recommendations based on the NCCN guidelines, a life expectancy variable was
created using age at diagnosis and the Social Security Administration Life Table of life
expectancy for males. Life expectancy was grouped into the following 3 categories in order to
determine appropriate treatment recommendation comparisons, 1) life expectancy greater than
or equal to 20 years, 2) life expectancy 10-19 years, 3) life expectancy less than 10 years.
Using the current study population of 85,694 cases, AA men represent 16.5% of the
study population and NHW men represent 83.5% of the study population. The life expectancy
distribution by race/ethnicity based on the 85,694 study population is represented below in
Table 20. Stratifying life expectancy by race/ethnicity indicates that AA men were more likely to
have a life expectancy of 20 years or more compared to NHW men (41% versus 23%). On the
other hand, NHW men were more likely to have a life expectancy 10-19 years (60% versus
52%) and <10 years (15% versus 7%) compared to AA men.
Table 20. Life Expectancy and Race/Ethnicity for Cases with AJCC TNM T Stage, N=85,694.
Race/Ethnicity
Demographic and
Clinical
Characteristics

AA (n=14,176)

NHW
(n=71,518)

Life Expectancy

P-value
<0.0001

20+ years

5,746 (40.5%)

18,162 (23.4%)

10-19 years

7,402 (52.2%)

42,732 (59.8%)

<10 years

1,028 (7.3%)

10,624 (14.9%)
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Assessment of Adherence to the NCCN Initial Treatment Recommendation
Results by Race/Ethnicity
Evaluating the NCCN initial treatment recommendations from 2004-2009 by
race/ethnicity indicate that low risk AA men with a life expectancy less than 10 years were less
likely to receive the NCCN initial treatment recommendations compared to NHW men with the
same life expectancy (5% versus 13%) (Table 21). On the other hand, AA men with 10 or more
years of life expectancy were more likely to receive the NCCN initial treatment recommendation
compared to NHW men (65% versus 61%). There were no race/ethnic differences in NCCN
initial treatment among men in the intermediate risk group with 10 or more years of life
expectancy. Seventy five percent (75%) of AA and NHW men with intermediate risk and 10 or
more years of life expectancy received the NCCN initial treatment recommendations. However,
only 2% and 5% of AA and NHW men, respectively, received the NCCN initial treatment
recommendation among those with intermediate risk and less than 10 years of life expectancy.
Table 21. Summary of the Percentage of Cases that Met the NCCN Treatment
Recommendations by AJCC T stage and Race/Ethnicity, 2004-2009.
Race/Ethnicity
AJCC TNM T Stage
Low Risk
< 10 years life
expectancy
>= 10 years life
expectancy
Intermediate Risk
< 10 years life
expectancy
>= 10 years life
expectancy
High Risk
All years of life
expectancy
Very High Risk

AA

NHW

NCCN Initial Treatment
Recommendation

5%

13%

Expectant management or RT

65%

61%

Expectant management or RT or
Surgery

2%

5%

Expectant management or RT or
Surgery

75%

75%

RT or Surgery

86%

88%

Hormone + RT or RT or Surgery
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Table 21 (Continued)
All years of life
expectancy
All years of life
expectancy

27%
76%

23%

2004-2007 - Hormone or RT +
Hormone

70%

2008-2009 - Hormone or RT +
Hormone or Surgery

Results by Age at Diagnosis
The results by age at diagnosis indicate that none (0%) of the men in the low risk or
intermediate risk groups less than 75 years of age with less than 10 years of life expectancy
received the NCCN initial treatment recommendations (Table 22). On the other hand, over 70%
of men in the same age group, less than 75 years of age, received the NCCN initial treatment
recommendation if they had 10 or more years of life expectancy. Over 80% of the men in the
high risk group received the NCCN initial treatment recommendation across all age groups.
Among those in the very high risk group, there was 51% or more compliance with the NCCN
initial treatment recommendations from 2008-2009 when the guideline was changed to add
surgery as a possible treatment recommendation compared to 2004-2007 when the NCCN
initial treatment compliance was less than 50% or less across all age groups. There was not
much difference in adherence to the NCCN initial treatment recommendation for the 75+ age
group in the very high risk group over time, 50% compliance from 2004-2007 and 51%
compliance from 2008-2009.
Table 22. Summary of the Percentage of Cases that Met the NCCN Treatment
Recommendations by AJCC T stage and Age at Diagnosis, 2004-2009.
Age at Diagnosis
AJCC TNM T Stage
Low Risk
< 10 years life
expectancy

<50

50-64

65-74

75+

NCCN Initial Treatment
Recommendation

0%

0%

0%

45%

Expectant management or
RT

89

Table 22 (Continued)
>= 10 years life
expectancy
Intermediate Risk

87%

80%

72%

20%

Expectant management or
RT or Surgery

0%

0%

0%

35%

Expectant management or
RT or Surgery

94%

84%

74%

21%

RT or Surgery

89%

88%

88%

83%

Hormone + RT or RT or
Surgery

All years of life
expectancy

20%

14%

23%

50%

2004-2007 - Hormone or RT
+ Hormone

All years of life
expectancy

70%

70%

78%

51%

2008-2009 - Hormone or RT
+ Hormone or Surgery

< 10 years life
expectancy
>= 10 years life
expectancy
High Risk
All years of life
expectancy
Very High Risk

Results by Stage at Diagnosis
The results by stage at diagnosis indicate that men in the high risk group had the highest
compliance with the NCCN initial treatment recommendation across all stages of disease
compared to those in the low risk group, intermediate risk group and the very high risk group,
where compliance with the NCCN treatment recommendations were consistency 40% or higher
(Table 23). Older men, men in the low risk group with less than 10 years of life expectancy and
men with intermediate risk with less than 10 years of life expectancy had some of the lowest
percentages of compliance with the NCCN initial treatment recommendations.
Table 23. Summary of the Percentage of Cases that Met the NCCN Treatment
Recommendations by AJCC T stage and Stage at Diagnosis, 2004-2009.

Stage at Diagnosis

AJCC TNM T Stage
Low Risk

Localized

Regional
90

Distant

NCCN Initial
Treatment
Recommendation

Table 23 (Continued)
< 10 years life
expectancy
>= 10 years life
expectancy
Intermediate Risk
< 10 years life
expectancy
>= 10 years life
expectancy
High Risk
All years of life
expectancy
Very High Risk

All years of life
expectancy

All years of life
expectancy

12%

62%

3%

33%

8%

Expectant
management or RT

13%

Expectant
management or RT or
Surgery

4%

1%

8%

Expectant
management or RT or
Surgery

69%

62%

14%

RT or Surgery

50%

88%

42%

Hormone + RT or RT
or Surgery

0%

17%

55%

2004-2007 - Hormone
or RT + Hormone

53%

2008-2009 - Hormone
or RT + Hormone or
Surgery

0%

13

Results by Tumor Grade
The results by tumor grade indicate that men in the high risk group had 81% or higher
compliance with the NCCN initial treatment recommendation across all tumor grades (Table 24).
Men in the low risk group with less than 10 years of life expectancy were less likely to receive
the NCCN initial treatment recommendation with less than 15% compliance across all tumor
grades.

On the other hand, men in the low risk group with 10 or more years of life expectancy

had a compliance of 35% or more with the NCCN initial treatment recommendation. Men in the
high risk group diagnosed with tumor grade 1 had 100% compliance with the NCCN initial
treatment recommendation. This is the only time where 100% compliance with the NCCN initial
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treatment recommendation was determined after evaluating age at diagnosis, stage at
diagnosis and race/ethnicity.

Table 24. Summary of the Percentage of Cases that Met the NCCN Treatment
Recommendations by AJCC T stage and Tumor Grade, 2004-2009.
Tumor Grade
AJCC TNM T Stage
Low Risk
< 10 years life
expectancy
>= 10 years life
expectancy
Intermediate Risk

NCCN Initial Treatment
Recommendation

1

2

3

4

12%

11%

13%

12%

Expectant management or
RT

69%

70%

47%

35%

Expectant management or
RT or Surgery

2%

3%

5%

2%

Expectant management or
RT or Surgery

90%

85%

66%

61%

RT or Surgery

100%

93%

86%

81%

Hormone + RT or RT or
Surgery

All years of life
expectancy

25%

16%

25%

24%

2004-2007 - Hormone or RT
+ Hormone

All years of life
expectancy

0%

76%

71%

61%

2008-2009 - Hormone or RT
+ Hormone or Surgery

< 10 years life
expectancy
>= 10 years life
expectancy
High Risk
All years of life
expectancy
Very High Risk

Summary of Findings for Research Question 2
In summary there were differences in the adherence of the NCCN initial treatment
recommendations/guidelines by race/ethnicity, age at diagnosis, tumor grade and stage at
diagnosis. Although, the current FCDS dataset provide support that men in the high risk and
very high risk groups are more likely to receive the NCCN initial treatment recommendation
compared to men in the low risk group and intermediate risk group.

In addition, this study

identified that men 75 years of age and older were less likely to receive the NCCN initial
treatment recommendations compared to men less than 75 years of age. Likewise, men with
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less than 10 years of life expectancy were less likely to receive the NCCN initial treatment
recommendations compared to men with 10 year or more life expectancy. Further research is
needed in this area to ascertain additional data on whether or not men are following the other
NCCN initial treatment recommendations such as having a DRE every 12 months and a PSA
test every 6 months. Having this additional clinical information will enhance the usefulness and
application of the results in clinical practice.
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CHAPTER FIVE: DISCUSSION
The importance of conducting research on the patterns of care among Florida residents
with prostate cancer is that we were able to add to the current body of knowledge regarding
disparities in treatment. In addition, we were able to highlight areas that need additional
research focus while continuing to enhance our understanding of why AA men were more likely
to be diagnosed with advanced disease at a younger age compared to NHW men. Moreover,
we were able to determine compliance with the NCCN initial treatment recommendations.
Study Strengths
The primary strength of utilizing the FCDS data is that it represents a population based
statewide Cancer Registry database. Secondly, FCDS has achieved 12 consecutive years of
gold status from NAACCR indicating the submission of high quality, timely and accurate data.
Thirdly, in addition to data edit checks, cancer registries are beginning to incorporate clinical edit
checks in order to identify missing/incomplete tumor characteristics, site specific factors and first
course of treatment (based on Commission on Cancer National Quality Forum, ASCO, NCCN
and NPCR). This has already been implemented with the Commission on Cancer (CoC)
approved programs; however, clinical edits are not currently required by NPCR or FCDS. When
the clinical edits are added as a requirement for FCDS data this will enhance the usefulness of
the treatment data because there will be verification that the treatment received has been
evaluated and reviewed for compliance to certain treatment standards. This will further provide
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an enhancement to the use of Cancer Registry data at the state level as a data source in
potentially evaluating clinical pathway treatment adherence. Lastly, utilizing the FCDS dataset
allowed the evaluation of treatment modalities administered to PrCa cases in the State of
Florida. To confirm that it is possible to use FCDS data to evaluate the first course of treatment
patterns, a study by Williams et al evaluating racial differences in treatment patterns among
pathologically confirmed primary ovarian cancer patients utilized FCDS data (Williams et al,
2010). The authors concluded that AA women who were diagnosed with ovarian cancer or
elsewhere and received all or part of first course of treatment in the State of Florida were less
likely to receive surgery and chemotherapy, the standard care of treatment, compared to NHW
women, adjusted OR = 0.79, 95% CI (0.68-0.91), p-value = 0.001. (Williams et al, 2010). In
addition, previous studies evaluated PrCa treatment patterns using data at the national level
such as NAACCR, NCDB, SEER data, SEER-Medicare linked data; however, Florida is a
NAACCR state but every hospital/facility in the State of Florida is not accredited by the
American College of Surgeons Commission on Cancer who is responsible for the NCDB data
(Shaver et al, 2004; Shimer, 2013; Mettlin, 1997). Next, Florida is not a SEER state
(www.SEER.cancer.gov , List of SEER Registries, 2014) so this study adds to the body of
knowledge in treatment patterns among PrCa patients in Florida compared to those in the
SEER states. Finally, physicians have clinical freedom and use of expertise to best treat their
patients and the NCCN treatment recommendations are used as a treatment guideline so one
would not expect 100% compliance because every patient is not treated the same due to
differences in clinical and demographic and molecular characteristics.
Study Limitations
The primary limitation of utilizing the FCDS data is that a researcher is not able to
evaluate the receipt of specific chemotherapy, immunotherapy or hormone drugs/regimens at
the cycle or dosage level because these levels of details are not required data elements to be
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collected and/or reported by FCDS. Secondly, the FCDS data does not allow one to determine
whether or not a patient was seen by a specialist such as a Urologic Oncologist or if their
prostatectomy was performed by an Urologic surgeon versus a General Surgeon. In order to
obtain this information data linkage with other statewide hospital data are required. In the case
of PrCa, this is especially important when evaluating access to care and if a patient was seen by
a medical professional with expertise in urologic oncology (Jang et al, 2010). The third
limitation, is that FCDS started collecting PrCa cases that were diagnosed and treated in private
physician offices in 2012 (Dr. Jill MacKinnon presentation at FCDS annual conference on
7/25/13). This opens the opportunity of potentially underestimating the number of prostate
cancer cases in the State of Florida before 2012 if a patient was never diagnosed and/or treated
at a hospital or facility that reported data to FCDS before 2012. Incorporating a link to claims
data and hospital electronic medical record data would allow one to capture the missed prostate
patients seen in the physician offices before 2012 in order to evaluate ICD-9 diagnosis codes
and CPT procedure codes to determine first course of treatment patterns (Hernandez et al,
2013). For example, linking the FCDS data to the Agency for Healthcare Administration (AHCA)
data can provide additional treatment and co-morbidity information for the PrCa patients.
Fourthly, Psychiatric, Military and the Veterans Administration (VA) facilities are not required to
report their cancer cases to FCDS, they have the option of voluntarily submitting cancer cases
to FCDS (FCDS, 2014); therefore, active duty or retired servicemen who were diagnosed at the
VA and received all of their first course treatment at the VA may not be represented in the
FCDS dataset. Next, collection of salvage treatment information, recurrence data or
progression information are not required by state or national standards so evaluating disparities
in recurrence or progression and treatment requires manual chart abstraction. Also, family
history of prostate cancer is one of the strongest risk factors that we were not able to evaluate in
this study because family history of cancer or a personal history of cancer was not a required
96

data element collected by FCDS. In addition, socioeconomic status and income data elements
are not routinely collected by cancer registries so this information was not available for inclusion
in this study. On the other hand, Gleason score was developed by Donald Gleason in 1996 and
it is the consensus grading system for prostate cancer; however, the cancer registry did not
implement Gleason score with the collaborative staging variables until 2004 (Epstein et al,
2005); therefore, tumor grade was used in this study instead of Gleason score in order to have a
consistent variable collected over the entire time period. Finally, recurrence or treatment
administered after a documented recurrence was not documented at the local or state level;
therefore, adherence to the NCCN treatment guidelines for patients with a disease free time
period that later developed persistent or recurrent disease was not evaluated in this study.
Consistency and Inconsistency with the Literature
The results stratified by race/ethnicity and stage at diagnosis were partially consistent
with previous research conducted by Xiao and colleagues who utilized FCDS data to evaluate
treatment modalities administered to localized PrCa cases (Xiao et al, 2009). For example, the
results from Xiao and colleagues and this study both had the same conclusion that AA men
diagnosed with localized PrCa were more likely to receive no definitive treatment; however, the
inconsistencies in both studies was that Xiao determined that AA men with localized disease
were less likely to receive radiation (25.3% versus 26.6%) and no difference was obtained for
race/ethnicity in the receipt of surgery (33.3% versus 32.7%) (Xiao et al, 2009). The results,
based on the adjusted OR, of this study determined that AA men with localized disease were
more likely to receive radiation therapy (adjusted OR=1.04, 95% CI (1.01, 1.07) and less likely
to receive surgery (adjusted OR=0.66, 95% CI (0.63, 0.68). On the other hand, Polednak and
Flannery determined that AA men with localized disease were less likely to receive no treatment
(9.8% versus 10.2%) or surgery (6.8% versus 10.8%) and more likely to receive radiation
(15.8% versus 13.5%) compared to White men (Polednak and Flannery, 1992). Likewise,
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Mettlin and colleagues determined that AA men were less likely to receive surgery (22.3%
versus 29.1%) compared to White men (Mettlin et al, 1997) and Cooperberg determined that AA
men were less likely to receive surgery (44.5% versus 50.7%) compared to White men
(Cooperberg et al, 2010). Also, Underwood and team evaluated localized and regional PrCa
cases and determined that AA were less likely to receive surgery compared to White men,
30.6% versus 35.4% (Underwood et al, 2004).
Stewart and colleagues determined that physicians following the 2014 NCCN and AUA
guidelines for renal cell carcinoma can miss up to 60% of recurrences due to the recommended
short surveillance or follow-up period after a nephrectomy (Stewart et al, 2014). This study
highlights the point that NCCN provides treatment guidelines and each physician has clinical
freedom to treat their patients weighing the benefits and risks of each treatment modality.
Regarding age at diagnosis and treatment, Skolarus and team determined that
men 75 years of age and older were more likely to receive active surveillance (57%) compared
to radiation therapy (37%) and surgery (6%) (Skolarus, 2014) while the results of this study
determined that men 75 year of age and older were more likely to receive no first course of
treatment (adjusted OR=1.19, 95% CI (1.11, 1.27)) and less likely to receive surgery (adjusted
OR=0.56, 95% CI (0.44, 0.72)) or radiation (adjusted OR=0.72, 95% CI (0.67, 0.77)). On the
other hand, the results of Skolarus indicate that men 65-74 years of age were more likely to
receive radiation (42%) versus surgery (33%) or active surveillance (Skolarus, 2014). In
addition, men less than 65 years of age were more likely to receive surgery (57%) versus
radiation (25%) or active surveillance (18%). With age at diagnosis there seems to be a shift in
younger men, less than 65 years of age, to receive more invasive treatment modalities such as
surgery (57%) while older men, 75 years of age and older, less likely to receive more invasive
treatment such as surgery (6%) (Skolarus et al, 2014).
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In summary, the results of this study have aspects that are consistent with the current
literature, such as AA men being less likely to receive surgery as part of first course of
treatment. On the other hand, there is no consensus on the receipt of treatment for AA and
NHW men regarding other treatment modalities such as radiation therapy, hormone therapy and
no treatment.
Public Health Importance
To highlight the Public Health Importance of this study, the results of this study can be
used to inform both the healthcare professional and patients diagnosed with prostate cancer
about the treatment modalities administered and how those treatment modalities compare to the
NCCN initial treatment recommendations. In addition, the results of this study can also be used
to educate clinicians and other healthcare professionals that provide care to patients diagnosed
with prostate cancer on the treatment disparities that exist by race/ethnicity, age at diagnosis,
stage at diagnosis and tumor grade. The results of this study are generalizable to men newly
diagnosed with prostate cancer who received all or part of first course of treatment in the State
of Florida and their data was reported to the Florida Cancer Data System.

Future Research
One of the major findings of this study is that AA men were less likely to receive surgery
or surgery in combination with other treatment modalities compared to NHW men. Skolarus et
al, 2014 provide survivorship care guidelines for prostate cancer patients after they receive
various treatment modalities and what clinicians and other healthcare providers can expect in
terms of assisting patients in managing their health after prostate cancer diagnosis. For
example, the authors indicate that “treatment regret” is more common among AA men who have
surgery (Skolarus et al, 2014). More research is needed in this specific area to understand why
AA men have surgical treatment regret compared to other race/ethnic groups. For example,
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from a qualitative research perspective, creating focus groups with the managing physicians
and prostate cancer patients together and separately is important to better understand why AA
men are more likely to elect palliative treatment options such as watchful waiting versus more
curative treatment options such as active surveillance, surgery or radiation.
From a business perspective with the Accountable Care Organizations (ACO), it will be
important to know the cost of the extent of prostate cancer associated treatments (i.e. surgery,
radiation therapy, hormone therapy, chemotherapy) received by patients in Florida. Do the
costs vary by facility, physician, geographic location in Florida, etc? How does the cost of
prostate cancer treatment in Florida compare to other states? Are there disparities in the cost of
treatment by race/ethnicity, age at diagnosis, stage at diagnosis, tumor grade for prostate
cancer patients in the State of Florida? Also, the implementation of ACO is changing the
payment structure of healthcare services from a fee for service to potentially a bulk payment for
a series of services administered to a patient based on tumor grade, stage, etc. Will this affect
payment cost of treatment as healthcare payers move from a fee for service type of payment
system meaning that each and every service has a charge to a more value based approach
where a payer pays a one-time fee based on the total estimated cost of treatment? With the
implementation of the Affordable Care Act, it will be important to see if there are any differences
in men seeking more invasive care/treatment that have insurance, this plays along with SES
and may possibly negate the current literature that there are differences because a patient does
not have health insurance. Now, the research question(s) can be asked in terms of what
happens if a patient has health insurance? Do we now focus on access to a medical oncologist,
surgical oncologist, radiation oncologist, or specialist in oncology versus a general internal
medicine physician?
Defensible next steps that can be shared with patients are to focus on what is in their
control such as primary prevention and modifiable risk factors. For example, encourage men to
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decrease red meat and fat consumption and increase consumption of vegetables and fruit. In
addition, 30 minutes of exercise per day, practicing safer sex that limit/reduce exposure to
sexually transmitted diseases, having annual physical examinations and DREs (especially AA
and high risk men under the age of 50), limit/reduce tobacco use and limit/reduce alcohol
consumption all play a role in potentially reducing cancer risk.
A valuable next step is to link to the FCDS data to the Centers of Medicare and Medicaid
Services (CMS) and AHCA data in order to identify additional procedures/treatments
administered to the patients and to identify the Medicare eligible patients to evaluate the
treatment patterns of AA men who are 65 years of age and older. Penberthy and colleagues
indicate that medical claim data enhance the completeness of cancer registry treatment data
because data from community providers increase the amount of data available for cancer
patients (Penberthy, 2014). Another valuable next step is to evaluate the PrCa treatment
patterns among Hispanic men in Florida. Hispanics represent 24% of Florida’s total population
compared to 17% in the U.S. (US Census Bureau, 2015). Hispanic men may have different
treatment patterns and other barriers to receiving treatment compared to AA or NHW men.
Also, it will be interesting to know if there are any disparities within the Hispanic community by
comparing treatment patterns among Cuban, Puerto Rican, Mexican, Dominican Republic and
South/Central American men. Given Florida’s increasing population of Hispanics, this study
would be a viable next step so that Hispanic men are aware of and receive the education
needed in order to make appropriate health care and treatment decisions.

Conclusion
This study adds to the current body of knowledge as it relates to detectable differences
in treatment strategies among AA men compared to NHW men in Florida newly diagnosed with
pathologically confirmed PrCa and how these strategies embody the contemporary NCCN
treatment recommendations. The results of this study indicate that AA men in Florida were
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more likely to receive radiation or hormone therapy as part of first course treatment and less
likely to receive surgery as part of first course treatment compared to NHW men. In addition,
AA men in the low risk group with 10 or more years of life expectancy and AA men in the very
high risk group were more likely to have compliance with the NCCN initial treatment
recommendations compared to NHW men. Further research is needed in the area of treatment
disparities and prostate cancer in order to evaluate additional potential confounders that were
not available for analysis in the FCDS dataset.
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Appendix A. Description of First Course of Treatment

Source: FCDS, Data Acquition Manual, 2013
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Appendix B. NCCN Clinical Practice Guidelines for Prostate Cancer
v1.1996 and v1.1977
Recommended Initial Treatment Based on Clinical Stage
T1a
• >10 year LE or Gleason score >7 or PSA post-TUR >10ng/ml then observation or
radiation or surgery
T1b, T1c, T2a, T2b, T2b
• High
o <10 year LE – no treatment or radiation
o 10-20 year LE – no treatment or radiation or surgery
o >20 year LE – radiation or surgery
• Moderate
o <10 year LE – no treatment or radiation
o >10 year LE – radiation or surgery
• Low
o <10 year LE - <10 year LE – no treatment or radiation
o >10 year LE – radiation or surgery
T3a
• Androgen ablation or combination radiation and/or androgen ablation
T3b, T3c, T4 N0
• Androgen ablation or radiation or combination radiation and/or androgen ablation
Tx N1-3
• Androgen ablation and/or radiation or observation
TxNxM1
• Androgen ablation
v1.1999
T1a
• Observation or radiation or surgery
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Appendix B

NCCN Treatment Guidelines (v1.2011)
Hypothesis 2/Aim 2
Low to high risk of recurrence
Primary Treatment
– T1c
•
•

•

<20 yrs = No tx/start AS
>=20 yrs = No tx/start AS or
RT or HT

•

– T1-T2a
• <10 yrs = No tx/start AS
• >=10 yrs = No tx/start AS or
RT or HT
– T2b-T2c
• <10 yrs = No tx/start AS or RT
w/ or w/o HT for 4-6 mths

•
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T3a

– RT and HT for 2-3 years or RT w/
or w/o HT for 4-6 mths OR Surg
T3b-T4
– Same as T3a or HT only
Mets at Dx
– Any T, N1, Mo
• HT or RT and HT for 2-3
years
– Any T, any N, M1
• HT

Appendix B
NCCN Initial Treatment Time period, 2003-2009
•

•

Low risk group
o T1-T2a
 <10 years life expectancy
• NCCN initial treatment recommendation is expectant management or
radiation therapy
 ≥ 10 years life expectancy
• NCC initial treatment recommendation is expectant management or
radiation therapy or surgery
Intermediate risk group
o T2b-T2c
 <10 years life expectancy
• NCCN initial treatment recommendation is expectant management or
radiation therapy or surgery
 ≥ 10 years life expectancy
• NCCN initial treatment recommendation is radiation therapy or
surgery

Appendix B
•

•

High risk group
o T3a
 NCCN initial treatment recommendation is radiation therapy, surgery or a
combination of radiation therapy and hormone therapy
 Note: there are no treatment recommendations by life expectancy
Very high risk group
o T3b-T4
 2003-2007
• NCCN initial treatment recommendation is hormone therapy or a
combination of hormone therapy and radiation therapy
 2008-2009
• NCCN initial treatment recommendation is hormone therapy,
combination of radiation therapy and hormone therapy or surgery
• Note: there are no treatment recommendations by life expectancy
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Appendix B
NCCN Initial Treatment Time period, 2010
•

•

•

•

Low risk group
o T1-T2a
 <10 years life expectancy
• NCCN initial treatment recommendation is active surveillance
 ≥10 years life expectancy
• NCCN initial treatment recommendation is active surveillance,
radiation therapy or surgery
Intermediate risk group
o T2b-T2c
 <10 years life expectancy
• NCCN initial treatment recommendation is active surveillance or
radiation therapy with or without hormone therapy or surgery
 ≥10 years life expectancy
• NCCN initial treatment recommendation is surgery or radiation
therapy with or without hormone therapy
High risk group
o T3a
 NCCN initial treatment recommendation is radiation therapy and hormone
therpy or surgery
Very high risk group
o T3b-T4
 NCCN initial treatment recommendation is surgery, hormone therapy, or a
combination of radiation therapy and hormone therapy
• Note: there are no treatment recommendations by life expectancy
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Appendix B
NCCN Initial Treatment Time period, 2011-2012
•

•

•

•

•

Very low risk group
o T1c
 <20 years life expectancy
• NCCN initial treatment recommendation is active surveillance
Low risk group
o T1-T2a
 <10 years life expectancy
• NCCN initial treatment recommendation is active surveillance
 ≥10 years life expectancy
• NCCN initial treatment recommendation is active surveillance,
radiation therapy or surgery
Intermediate risk group
o T2b-T2c
 <10 years life expectancy
• NCCN initial treatment recommendation is active surveillance or
radiation with or without hormone therapy
 ≥10 years life expectancy
• NCCN initial treatment recommendation is surgery or radiation
therapy with or without hormone therapy
High risk group
o T3a
 NCCN initial treatment recommendation is surgery or radiation therapy with
or without hormone therapy
Very high risk group
o T3b-T4
 NCCN initial treatment recommendation is hormone therapy, surgery or
radiation therapy with or without hormone therapy
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Appendix C. Detailed Proposed Inclusion/Exclusion Criteria
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Appendix D. FCDS List of Available Data Elements
NAACCR
Item #

Year Started12
Ended
STAT CD

Ite
m
Na
me

Limited
13
1
CD
Full CD

Special
5
Studies

4

2875

CS Site-Specific Factor 21

2010

X

X

X

2876

CS Site-Specific Factor 22

2010

X

X

X

2877

CS Site-Specific Factor 23

2010

X

X

X

2878

CS Site-Specific Factor 24

2010

X

X

X
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2879

CS Site-Specific Factor 25

2010

X

X

X

2880

CS Site-Specific Factor 1

2004

X

X

X

2890

CS Site-Specific Factor 2

2004

X

X

X

2900

CS Site-Specific Factor 3

2004

X

X

X

2910

CS Site-Specific Factor 4

2004

X

X

X

2920

CS Site-Specific Factor 5

2004

X

X

X

2930

CS Site-Specific Factor 6

2004

X

X

X

2935

CS Version 1

2004

X

X

X

2936

CS Version Latest

2004

X

X

X

2937

CS Version Input Current

2010

X

X

X

2940

Derived AJCC T

2004

X

X

X

st
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2950

Derived AJCC T Descriptor

2004

X

X

X

2960

Derived AJCC N

2004

X

X

X

2970

Derived AJCC N Descriptor

2004

X

X

X

2980

Derived AJCC M

2004

X

X

X

2990

Derived AJCC M Descriptor

2004

X

X

X

3000

Derived AJCC Stage Group

2004

X

X

X

3030

Derived AJCC—Flag

2004

X

X

X

3040

Derived SS1977—Flag

1981

X

X

X

X

3050

Derived SS2000—Flag

1981

X

X

X

X

3250

RX Summ--Transplnt/Endocr

2003

X

X

X

3400

Derived AJCC-7 T

2010

X

X

X
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3402

Derived AJCC-7 T Descript

2010

X

X

X

3410

Derived AJCC-7 N

2010

X

X

X

3412

Derived AJCC-7 N Descript

2010

X

X

X

3420

Derived AJCC-7 M

2010

X

X

X

3422

Derived AJCC-7 M Descript

2010

X

X

X

3430

Derived AJCC-7 Stage Grp

2010

X

X

X

Source: FCDS (9/28/2010)
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Appendix E. Preliminary Demographic and Clinical Characteristics Tables

Table 9. Overall Demographic Characteristics of Prostate Cancer Cases (March 2013),
N=356,787 (Source: FCDS Aggregate Stat CD)
Demographic or Clinical Characteristic
Date of Diagnosis (5 years)
1982-1986
1987-1991
1992-1996
1997-2001
2002-2006
2007-2011

Frequency

Percentage

27740
51142
69342
71893
69065
67605

7.77
14.33
19.44
20.15
19.36
18.95

Primary Race
White
Black
Other
Unknown

313087
38522
1432
3746

87.75
10.8
0.4
1.05

Spanish/Hispanic Origin
Non-Hispanic
Hispanic
Unknown

320769
32512
3506

89.9
9.11
0.98

Gender
Male
Female
Other/Unknown

356724
44
19

99.98
0.01
0.01

Address at Diagnosis (State)
Florida

356787

100

Sequence Number (Central)
0
1
2

279340
48573
25154

78.29
13.61
7.05
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3
4
5
6
7
8

3188
434
76
18
3
1

0.89
0.12
0.02
0.01
0
0

FCDS Age Group
0-4
5-9
10-14
15-19
20-24
25-29
30-34
35-39
40-44
45-49
50-54
55-59
60-64
65-69
70-74
75-79
80-84
85+
Unknown

7
3
1
11
5
4
9
103
1005
4330
12963
26656
46117
74769
78421
61177
32547
18643
16

0
0
0
0
0
0
0
0.03
0.28
1.21
3.63
7.47
12.93
20.96
21.98
17.15
9.12
5.23
0

Marital Status at Diagnosis
Married
Widowed, Divorced, Separated, Single
Unknown

266463
76988
13336

74.68
21.58
3.74

4186

1.17

77899

21.83

3764

1.05

137500

38.54

Primary Payer at Diagnosis
Not insured; not insured self-pay
Insurance NOS; Private insurance;
Managed care, HMO, PPO, Private
Insurance fee for service
Medicaid; Medicaid administered
through a managed care plan
Medicare; Medicare NOS; Medicare
with supplement NOS; Medicare
administered through managed care
plan; Medicare with private
supplement; Medicare with Medicaid
eligibility
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Tricare, Military, Veterans Affairs,
Indian/Public health service
Unknown

4895

1.37

128543

36.03

Table 10. Overall Clinical Characteristics of Prostate Cancer Cases (March
2013), n= 356,787
Clinical Characteristic

Frequency

Percentage

Positive histology

344187

96.47

Positive cytology

2101

0.59

Positive microscopic confirmation but
method unknown

132

0.04

Positive lab marker

1608

0.45

Direct visual without microscopic
confirmation

56

0.02

Radiography without microscopic
confirmation

958

0.27

Clinical diagnosis only

799

0.22

Unknown whether microscopic confirmed

6946

1.95

In situ

675

0.33

Local

127907

62.34

Regional/Direct Extension

15025

7.32

Regional/Nodes Only

2483

1.21

Regional/Direct extension and Nodes

1328

0.65

Regional NOS

1207

0.59

Distant/Systemic Disease

16828

8.2

Diagnostic Confirmation

SEER Summary Stage, 1977
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Unknown

39723

Missing

151611

19.36

SEER Summary Stage, 2000
In situ

73

0.05

Local

122212

80.6

Regional/Direct Extension

9563

6.31

Regional/Nodes Only

604

0.4

Regional/Direct extension and Nodes

550

0.36

Regional NOS

37

0.02

Distant/Systemic Disease

5368

3.54

Unknown

13215

8.72

Missing

205165

Grade/Differentiation
1, Grade 1

37734

10.58

2, Grade 2

166025

46.53

3, Grade 3

89040

24.96

4, Grade 4

3230

0.91

5, T-cell

1

0

6, B-cell

1

0

8, Natural killer cells

3

0

9, Grade unknown

60753

17.03
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Appendix F. Social Security Administration, Life Expectancy Table Stratified by Exact
Age
Period Life Table, 2009
Exact age
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
132

Life
expectancy
41
40.07
39.15
38.23
37.31
36.4
35.5
34.6
33.7
32.82
31.94
31.06
30.2
29.35
28.5
27.66
26.84
26.02
25.21
24.41
23.61
22.82
22.04
21.27
20.5
19.74

63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90

18.99
18.24
17.51
16.79
16.08
15.39
14.7
14.03
13.37
12.72
12.09
11.47
10.87
10.28
9.71
9.16
8.62
8.1
7.6
7.12
6.66
6.22
5.8
5.4
5.02
4.66
4.33
4.02

Source: http://www.ssa.gov/OACT/STATS/table4c6.html
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Appendix G. Applied Inclusion/Exclusion Criteria

APPLIED INCLUSION/EXCLUSION CRITERIA

Site Group =
prostate
N=356,787 cases

Sequence number
≠0

Sequence number
=0
n = 279,340

Address at
diagnosis state ≠
Florida

Address at
diagnosis state =
Florida
n= 279,340

Behavior ≠
malignant

Behavior =
malignant
n=278,873

Diagnostic
confirmation ≠
pathologic

Diagnostic
confirmation =
pathologic only
n=268,098

Race ≠ White or
African American

Race = White or
African American
n=263,457

Histology type ≠
‘Adeno’

Histology type =
‘adeno’
n=227,799

Non-Hispanic African
American
n=29,087
(13%)

Non-Hispanic
White
n=198,712
87%

‘Adeno’ defined according to the following ICDO-3 histology codes: 8410, 8141, 8143, 8147, 8200, 8211, 8255, 8260, 8262,
8310, 8380, 8480, 8481, 8490, 8550, 8551, 8560, 8570, 8574 and 9070 (Fritz et al, 2000)

Page 1
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Appendix H. Proposed Timeline
Detailed Timeline by Month, June 2013 – December 2014
Month

Jun13

Jul13

Aug13

Sep-13

Oct13

Complete writing
of dissertation
Outline and
Proposal

X

X

X

X

X

Defense and
Presentation of
Dissertation
Proposal

Obtain USF IRB
and FDOH IRB
approval

Nov13

Dec-13

X

X

Jan14

X
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Feb14

Mar14

Apr14

May14

Jun14

Jul-14

Aug14

Sept14

Oct14

Nov
- 14

Dec
- 14

Month

Data Cleaning

Jun13

Jul13

Aug13

Sep-13

Oct13

Nov13

Dec-13

Jan14

Feb14

X

X

X

Data Analysis

X

Prepare
Dissertation
Results,
Discussion and
Conclusion

Mar14

Apr14

May14

Jun14

Jul-14

X

X

X

X

X

X

Prepare 2
manuscripts for
submission
Preparation for
Mock Defense
Dissertation
Defense

Aug14

X

Sept14

Oct14

X

X

Nov
- 14

X

X

X

X

Dec
- 14

X

Make any
recommended
changes and/or
updates to final
dissertation
Submit final
manuscripts for
submission to
journals

X
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X

(January/February
2015)

Work with COPH
and Graduate
School to submit
dissertation in
correct format
and all of the
necessary
documentation
for graduation
(January – April
2015)
Final preparation
for graduation
(April 2015)
Graduation
(May 2015)
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Appendix I: University of South Florida Institutional Review Board Approval
Letter

4/29/2014
Vonetta Williams
Environmental and Occupational Health
12902 Magnolia Drive
Mailstop: TCC-SRB, 21205
Tampa, FL 33612
RE: Expedited Approval for Initial Review
IRB#: Pro00016727
Title: Race/Ethnic Differences in Prostate Cancer Treatment Patterns among Newly Diagnosed
Prostate Cancer Patients in Florida.
Study Approval Period: 4/28/2014 to 4/28/2015
Dear Ms. Williams:
On 4/28/2014, the Institutional Review Board (IRB) reviewed and APPROVED the
above application and all documents outlined below.
Approved Item(s):
Protocol
Document(s):
Proposal with Appendix 4-14-14
It was the determination of the IRB that your study qualified for expedited review which
includes activities that (1) present no more than minimal risk to human subjects, and (2)
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involve only procedures listed in one or more of the categories outlined below. The IRB
may review research through the expedited review procedure authorized by
45CFR46.110 and 21 CFR
56.110. The research proposed in this study is categorized under the following expedited
review category:
(5) Research involving materials (data, documents, records, or specimens) that have been
collected, or will be collected solely for nonresearch purposes (such as medical treatment
or diagnosis).
Your study qualifies for a waiver of the requirements for the process of informed consent as
outlined in the federal regulations at 45CFR46.116(d) which states that an IRB may approve a
consent procedure which does not include, or which alters, some or all of the elements of
informed consent.
As the principal investigator of this study, it is your responsibility to conduct this study in
accordance with IRB policies and procedures and as approved by the IRB. Any changes to the
approved research must be submitted to the IRB for review and approval by an amendment.
We appreciate your dedication to the ethical conduct of human subject research at the
University of South Florida and your continued commitment to human research protections.
If you have any questions regarding this matter, please call 813-974-5638.
Sincerely,

E. Verena Jorgensen, M.D., Chairperson
USF Institutional Review Board
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Appendix J: National
Comprehensive Cancer Network
Permissions Request

ARCHIVED GLS
(INFO PURPOSES ONLY)

March 27, 2014
Vonetta L. Williams, MPH, CTR
Manager, Information Shared Services
USF Doctoral Candidate
Moffitt Cancer Center
Dear:
Enclosed is a copy of the Archive NCCN Guidelines for Prostate Cancer (all versions 1996-2012) for
your informational purposes and use in your dissertation only. You cannot represent your institution or
your institution’s guidelines as NCCN guidelines, NCCN-approved guidelines, or as having any other
connection to the NCCN. The following qualifications also apply:
These guidelines are a work in progress that will be refined as often as new significant data
becomes available.
The NCCN guidelines are a statement of consensus of its authors regarding their views of
currently accepted approaches to treatment. Any clinician seeking to apply or consult any NCCN
guideline is expected to use independent medical judgment in the context of individual clinical
circumstances to determine any patient’s care or treatment. The National Comprehensive Cancer
Network makes no warranties of any kind whatsoever regarding their content, use, or application
and disclaims any responsibility for their application or use in any way.
These guidelines are copyrighted by the National Comprehensive Cancer Network. All rights
reserved. These guidelines and illustrations herein may not be reproduced in any form for any
purpose without the express written permission of the NCCN.
The NCCN has the complete library of oncology practices guidelines available on a flash drive and on the
internet. To view the most recent version of the Guidelines, go online to www.nccn.org
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Thank you for your interest in the work of the NCCN.
Sincerely,

Kimberly Brydges
Kimberly Brydges
Business Development Specialist
National Comprehensive Cancer Network
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Appendix K: Florida Department of Health, Bureau of Epidemiology Approval

Williams, Vonetta L.
From:
Sent:
To:
Cc:
Subject:

Wohler, Brad <BWohler@med.miami.edu>
Monday, June 16, 2014 12:42 PM
Williams, Vonetta L.
'Tara.Hylton@flhealth.gov'
RE: DOH IRB - Moffitt Request (V. Williams)

Ms Williams,
Tara Hylton has directed that this request is free of charge.

“There will be no fee for this request as Ms. Williams is a student.”

Brad Wohler
Florida Cancer Data System
P.O. Box 016960 (D4-11)
Miami, FL 33101
 Tel.: (305) 243-5527



Email: bwohler@med.miami.edu

 Locator D4-11


Fax: (305) 243-4871
Overnight Courier:
1550 NW 10th Ave, Fox Bldg Rm 410
Miami, FL 33136

The information contained in this transmission may contain privileged and confidential information, including
patient information protected by federal and state privacy laws. It is intended only for the use of the person(s)
named above. If you are not the intended recipient, you are hereby notified that any review, dissemination,
distribution or duplication of this communication is strictly prohibited. If you are not the intended recipient,
please contact the sender by reply email and destroy all copies of the original message.
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Appendix L: American Cancer Society, Inc. Copyright License Agreement

-

.

American Cancer Society

June 30, 2014

COPYRIGHT LICENSE AGREEMENT
Vonetta L. Williams, MPH, CTR
Moffitt Cancer Center
12902 Magnolia Drive
Tampa, FL 33612
Vonetta. Williams@Moffitt.org

RE:PER.14.188
Dear Ms. Williams:
In accordance with the following terms and conditions, the American Cancer Society, Inc.
("ACS") grants your request to reprint content and a figure from the ACS article entitled "What
is Prostate Cancer?" in a dissertation titled "Race/Ethnic Differences in Prostate Cancer
Treatment Patterns Among Newly Diagnosed Prostate Cancer Patients in Florida" as set forth on
Exhibit A attached hereto and incorporated herein (the "Material"):
I.
The following credit line must be prominently placed on the page[s] in which the
Material appears:

"Reprinted by the permission of the American Cancer Society, Inc. All rights reserved."
2.

ACS grants Vonetta L. Williams the one-time, nonexclusive, nontransferable license to
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reproduce the Material in a dissertation titled "Race/Ethnic Differences in Prostate Cancer
Treatment Patterns Among Newly Diagnosed Prostate Cancer Patients in Florida." The Material
will not be sold.
3.
The rights granted herein are for the English language print including disability
accessible versions and an online platform used by the University of South Florida to access
dissertations and do not apply to revised editions, foreign language editions, or any other form of
print or electronic media. Use of the Material for future reproductions, translations, or any
derivative/ancillary works without the express written consent of ACS is prohibited. All rights
not expressly granted herein are exclusively reserved to ACS.
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4.
The Material must appear as set forth on Exhibit A. Deletions, alterations, or other
modification of ACS content is strictly prohibited. In addition, any other use of this or other
ACS material or information without the express written consent of ACS is prohibited.
5.
ACS does not endorse or promote any party or goods or services offered by third parties.
Accordingly, the Material shall not be used in any way that gives an implied or express
impression of affiliation with or endorsement by ACS.
Upon receipt of the executed agreement, permission will be granted to reproduce the Material.
Please return the originally executed agreement via (1) mail to the attention of TaSonja
Hibbler, American Cancer Society, Inc., 250 Williams Street, Atlanta, GA 30303, (2) email
to permissioureg uest@cancer.org or (3) fax to TaSonja Hibbler at 404-417-5808 . Should
you have any questions regarding this matter, please contact TaSonja Hibbler at 404-329-7638.

s;gMWre

Printed Name:
Date:
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Exhibit A

Chapter Two
Revle\V of the Literature

Study Background and Rationale
Anatomv of the Prostate Gland
Signaled by androgens, specifically testosterone, \Vhich is produced in the scrotum, the
prostate gland is part of the ma!e reproductive system and starts developing before birth and
continues to grow throughout puberty, with growth of the prostate gland slowing down at
adulthood (ACS, PC Overview, 2013). Anatomically located inferior to the bladder and anterior
to the rectun1, the purpose of the prostate gland is multi-faceted_ First, the prostate gland aids
in creating fluid that protect and nourish the sperm (ACS, PC Overview, 20-13). Secondly, the
prostate gland, working with the nervous systen1, serves as a valve to release sperm or urine
(ACS. PC Overview, 20 13).
Figure 1. Anaton1y of the Prostate

Picture retrieved from the American Cancer Society on August '15, 2013
(http://www.cancer.org/ cancer/prostatecancer/deta lledguide/ prostate-cancer -what-is-prostate
cancer}
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The type of tissue that comprises the prostate gland is primarily epithelial tissue_
Bostwick and colleagues indicate that approximately 95% of the PrCa tumors arise from the
epithelial cells producing histology of adenocarcinoma (Bostwick et al, '1 989)_ Adenocarcinoma
of the prostate gland will be the focus of this study; the rare PrCa histologic types that comprise
5% of PrCa cases, such as mucinous, ductal, neuroendocrine and small cell carcinoma will not
be addressed {Bostwick et al, 1989).
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Appendix M. Final Inclusion/Exclusion Criteria

INCLUSION/EXCLUSION CRITERIA
YEAR

OF

DX, 1982-2012

Include Primary Site = C619 (prostate)
N=395,951
Sex ≠ male (exclude female
(48), herm (5), Trans (5),
unknown (23)
N=81

Sex = males
N=395,870
11.05% of AA (43749/395870)
99.98% of total (395870/395951)

Include behavior code = malignant
N=395,084

Include Histology =
Adenocarcinoma
N=367,861

Include Master sequence
(central) number = 00 or 01
N=338,701

Include Diagnostic confirmation = pathology
or histologic confirmation, lab marker (all
except unknown)
N=337,872

Include Age at diagnosis ≥ 18 years
N=337,855

Include Primary Race (Race 1) = African American
(Black) or White
N= 332,464
11.60% of AA (38580/332464)
83.97% of total (332464/395951)

Include Spanish/Hispanic Origin (Ethnicity)
= Non-Hispanic or Non-Spanish
N=298,842

Include those with a known type of reporting
source for treatment documentation
N=298,810

Exclude behavior code ≠ malignant
(exclude in situ)
N=786

Exclude Histology ≠ Adenocarcinoma
(mucinous, ductal, signet ring cell, adenosquamous,
neuroendocrine, small cell ca)
N=27,223 with missing histology
Exclude Master sequence number
≠ 00 or 01
N=29,160

Exclude Diagnostic confirmation =
unknown how cancer was diagnosed
N=829

Exclude Age at diagnosis < 18 years
(N=1) and unknown age (N=17)
N=17

Exclude Primary Race (Race 1) ≠ African
American (Black) or White
N=5,391

Exclude Spanish/Hispanic Origin
(Ethnicity) ≠ Non-Hispanic or NonSpanish
N=33,622
Exclude those with type of reporting source = autopsy only
or death certificate only (no opportunity for tx)
N=32

Accounting for all missing and unknown treatment data
N=244,449
12.47% of AA (30476/244449)
62% of total (224449/395951)

Primary site is equal to prostate cancer. Analytic cases only (cases who were diagnosed and/or treated in Florida for all or part of first course treatment).
Excluded non-analytic cases (cases who came to a Florida hospital and they had already received all of part of their first course treatment, patients who
present with progressive, persistent or recurrence disease). Excluded second opinions, consultations, men with BPH (benign prostate hyperplasia) and
men with PIN III. Sequence number is equal to 0 (exclude patients that have multiple primary tumors. Histology is equal to adenocarcinoma only.
Diagnostic confirmation is equal to pathology.
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Appendix N
Table 11. Demographic and Clinical Characteristics of PrCa Cases by Race/Ethnicity,
N=244,449
Race/Ethnicity

Demographic and
Clinical
Characteristics

AA (n=30,476)

NHW (n=213,973)

Stage at Diagnosis
In situ

<0.0001

180,276 (84.25%)

Regional

0 (0.00%)
24,867
(81.60%)
3,058
(10.03%)

Distant

2,551 (8.37%)

10,823 (5.06%)

Localized

11 (0.01%)

22,863 (10.68%)

Age at diagnosis
(years)

Overall Average age,
Median age and Age
range

Average age (years)

P-value

<0.0001

68.86, 69.00, 29-105

65.31

69.36
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Median age (years)

65.00

70.00

Age range (years)

29-105

32-104

<50

1,295 (4.25%)
12,485
(40.97%)
11,923
(39.12%)
4,773
(15.66%)

3,162 (1.48%)

50-64
65-74
75+

53,993 (25.23%)
96,982 (45.32%)
59,836 (27.96%)

Insurance Payer

<0.0001

Not insured

1,025 (3.36%)

1,391 (0.65%)

Insurance, NOS

2,074 (6.81%)
8,650
(28.38%)

11,304 (5.28%)

Private insurance
Medicaid
Medicare
DOD/Tricare/VA
Unknown

1,050 (3.45%)
9,668
(31.72%)
801 (2.63%)
7,208
(23.65%)

37,531 (17.54%)
897 (0.42%)
83,279 (38.92%)
3,532 (1.65%)
76,039 (35.54%)

Tumor Grade
1

<0.0001

121,212 (56.65%)

3

2,863 (9.39%)
16,390
(53.78%)
10,933
(35.87%)

4

290 (0.95%)

2,082 (0.97%)

2

27,002 (12.62%)

63,677 (29.76%)

First Course
Treatment Modality
Received
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No first course
treatment

7,096
(23.28%)

Surgery (singular or
multimodality)
Surgery only

6,826
(22.40%)
6,171
(20.25%)

Radiation Therapy
(singular or
multimodality)

61,968 (28.96%)

<0.0001

40,469 (18.91%)

<0.0001

36,576 (17.09%)

<0.0001

13,475
(44.20%)

94,568 (44.22%)

0.9505

Radiation Therapy
only

8,331
(27.34%)

62,061 (29.00%)

<0.0001

Surgery and
Radiation

199 (0.65%)

1,035 (0.48%)

<0.0001

Hormone Therapy
(singular or
multimodality)

8,271
(27.14%)

50,654 (23.67%)

<0.0001

Hormone Therapy
only

2,961 (9.72%)

16,960 (7.93%)

<0.0001

Radiation and
Hormone Therapy

4,718
(15.48%)

30,216 (14.12%)

<0.0001

Surgery and
Hormone Therapy

334 (1.10%)

2,221 (1.04%)

0.3519

Surgery and
Hormone Therapy
and Radiation
Therapy

98 (0.32%)

505 (0.24%)

0.0048
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Chemotherapy
(singular or
multimodality)

152 (0.50%)

918 (0.43%)

0.0845

Immunotherapy
(singular or
multimodality)

12 (0.04%)

112 (0.05%)

0.3469

Other Therapy
(singular or
multimodality)

42 (0.14%)

297 (0.14%)

0.9654

Endocrine Therapy
(singular or
multimodality)

367 (1.20%)

1,171 (0.55%)

<0.0001

Other Therapy (other
tx only,
chemotherapy only,
endocrine therapy
only or
immunotherapy
only)

568 (1.86%)

2,431 (1.14%)

<0.0001

Marital Status

<0.0001

Ever married

4,780
(15.68%)
24,220
(79.47%)

193,960 (90.65%)

Unknown

1,476 (4.84%)

6,441 (3.01%)

Never married

13,572 (6.34%)

Vital Status

<0.0001
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Expired

11,210
(36.78%)

101,323 (47.35%)

Not known to be
expired

19,266
(63.22%)

112,650 (52.65%)

Year of Diagnosis

<0.0001

1982-1986

1682 (5.52%)

16,483 (7.70%)

1987-1991

2254 (7.40%)

30,391 (14.20%)

1992-1996

4269 (14.01%)

38,000 (17.76%)

1997-2001

5561 (18.25%)

41,512 (19.40%)

2002-2006

6616 (21.71%)
10094
(33.12%)

39,722 (18.56%)

2007-2012

47,865 (22.37%)
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Appendix N
Table 12. Demographic and Clinical Characteristics of PrCa Cases by Race/Ethnicity and Stage at Diagnosis (N=244,438)
Note: In Situ cases (n=11) were not included in this table

Race/Ethnicity
Localized
(n=205,143)

AA (n=24,867)
Demographic and
Clinical Characteristics
First Course Treatment
Modality
No First Course
Treatment

Regional
(n=25,921)
NHW
(n=180,276)

p-value

AA
(n=3,058)

NHW
(n=22,863)

606
(19.82%)
1,101
(36.00%)

6,264
(27.40%)
6,491
(28.39%)
363
(1.59%)
605
(2.65%)
591
(2.58%)
2,359
(10.32%)
3,772
(16.50%)
2,053
(8.98%)
365
(1.60%)

Surgery Only
Surgery + Radiation +
Hormone

5,057 (20.34%)

53,362
(29.60%)
30,003
(16.64%)

29 (0.12%)

128 (0.07%)

0.0147

Surgery + Radiation

86 (0.35%)

415 (0.23%)

0.0005

Surgery + Hormone

254 (1.02%)

1,601 (0.89%)

0.0373

Hormone Therapy Only

1,469 (5.91%)

<0.0001

Radiation Therapy Only

7,747 (31.15%)

Radiation + Hormone

4,068 (16.36%)

9,299 (5.16%)
57,526
(31.91%)
26,738
(14.83%)

<0.0001

72 (2.35%)
309
(10.10%)
419
(13.70%)
314
(10.27%)

Other Therapy

214 (0.86%)

1204 (0.67%)

0.0001

63 (2.06%)

5,943 (23.90%)

<0.0001
<0.0001

0.0164

Distant
(n=13,374)

64 (2.09%)
110
(3.60%)

154

p-value

AA
(n=2,251)

NHW
(n=10,823)

p-value

<0.0001

547
(21.44%)

2,335
(21.57%)

0.8842

<0.0001

13 (0.51%)

81 (0.75%)

0.194

0.0393

5 (0.20%)

14 (0.13%)

0.4214

0.0026

3 (0.12%)

15 (0.14%)

0.7947

0.4483

8 (0.31%)
1,183
(46.37%)
165
(6.47%)
336
(13.17%)
291
(11.41%)

29 (0.27%)
5,302
(48.99%)
760
(7.02%)
1,425
(13.17%)
862
(7.96%)

0.6929

0.7154
<0.0001
0.0202
0.0004

0.0175
0.3211
0.9947
<0.0001

Age at diagnosis (years)
Overall Average age and
Age range (years)
Average age (years)
Median age (years)
Age range (years)

<0.0001
68.89 (29-105)
65.15
69.41
65.00
70.00
29-105
32-104

<50

1,080 (4.34%)

50-64

10,197 (41.01%)

65-74

9,912 (39.86%)

75+

3,678 (14.79%)

68.77 (34-98)
63.40
67.23
63.00
67.00
36-95
34-98
168
438
(5.49%)
(1.92%)
1,510
7,555
(49.38%)
(33.04%)
1,060
10,877
(34.66%)
(47.57%)
320
3,993
(10.46%)
(17.46%)

2,603 (1.44%)
44,667
(24.78%)
82,115
(45.55%)
50,891
(28.23%)

Marital Status

<0.0001

<0.0001

Never married

3,814 (15.34%)

Ever married

19,802 (79.63%)

11,548 (6.41%)
163,073
(90.46%)

Unknown

1,251 (5.03%)

5,655 (3.14%)

Grade
2,559 (10.29%)

2

14,379 (57.82%)

3

7,795 (31.35%)

24,884
(13.80%)
107,788
(59.79%)
46,499
(25.79%)

72.37 (38-104)
69.19
73.12
69.00
73.00
39-104
38-101
121
47 (1.84%)
(1.12%)
778
1,771
(30.50%)
(16.36%)
951
3,981
(37.28%)
(36.78%)
775
4,950
(30.38%)
(45.74%)

<0.0001
446
(14.58%)
2,491
(81.46%)
121
(3.96%)

1,355
(5.93%)
20,975
(91.74%)
533
(2.33%)

<0.0001

1

<0.0001

<0.0001
520
(20.38%)
1927
(75.54%)
104
(4.08%)

668
(6.17%)
9903
(91.50%)
252
(2.33%)

<0.0001
132
(4.32%)
1,274
(41.66%)
1,606
(52.52%)

155

1264
(5.53%)
10,125
(44.29%)
11,051
(48.34%)

0.0077
172
(6.74%)
737
(28.89%)
1,532
(60.05%)

850
(7.85%)
3,292
(30.42%)
6,127
(56.61%)

4

134 (0.54%)

1,105 (0.61%)

Insurance Payer

46 (1.50%)

423
(1.85%)

189
(0.83%)
1,440
(6.30%)
3,991
(17.46%)

<0.0001
792 (3.18%)

1,102 (0.61%)

Insurance, NOS

1,727 (6.94%)

Private insurance

7,597 (30.55%)

9,663 (5.36%)
32,929
(18.27%)

97 (3.17%)
275
(8.99%)
853
(27.89%)

Medicaid

846 (3.40%)

Medicare

8,498 (34.17%)

736 (0.41%)
74,969
(41.59%)

95 (3.11%)
677
(22.14%)

DOD/Tricare/VA

719 (2.89%)

Unknown

4,688 (18.85%)

3,163 (1.75%)
57,714
(32.01%)

60 (1.96%)
1,001
(32.73%)

Expired
Not known to be
expired

92 (0.40%)
6,150
(26.90%)
300
(1.31%)
10,701
(46.80%)

<0.0001
7,715 (31.03%)
17,152 (68.97%)

79,111
(43.88%)
101,165
(56.12%)

Year of Diagnosis
931 (3.74%)

1987-1991

1346 (5.41%)

1992-1996

3150 (12.67%)

11652 (6.46%)
22275
(12.36%)
30856
(17.12%)

136
(5.33%)

100
(0.92%)
201
(1.86%)
610
(5.64%)

<0.0001

72 (2.82%)
200
(7.84%)
109
(4.27%)
493
(19.33%)

69 (0.64%)
2,158
(19.94%)

22 (0.86%)
1,519
(59.55%)

69 (0.64%)
7,616
(70.37%)

<0.0001
1,310
(42.84%)
1,748
(57.16%)

12,387
(54.18%)
10,476
(45.82%)

<0.0001

1982-1986

554
(5.12%)

<0.0001

Not insured

Vital Status

110
(4.31%)

<0.0001
2185
(85.65%)
366
(14.35%)

9815
(90.69%)
1008
(9.31%)

<0.0001
137
(4.48%)
314
(10.27%)
711
(23.25%)
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1657
(7.25%)
4779
(20.90%)
5601
(24.50%)

<0.0001
614
(24.07%)
594
(23.28%)
408
(15.99%)

3173
(29.32%)
3332
(30.79%)
1538
(14.21%)

1997-2001

4732 (19.03%)

2002-2006

5776 (23.23%)

2007-2012

8932 (35.92%)

36915
(20.48%)
35972
(19.95%)
42606
(23.63%)

539
(17.63%)
548
(17.92%)
809
(26.46%)
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3621
(15.84%)
2973
(13.00%)
4232
(18.51%)

290
(11.37%)
292
(11.45%)
353
(13.84%)

976
(9.02%)
777
(7.18%)
1027
(9.49%)
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Table 13. Adjusted Odds Ratios* (OR) and 95% Confidence Intervals of Prostate Cancer
Patients by Treatment, Race/Ethnicity and Stage at Diagnosis.

Adjusted
OR (95% CI)
Localized
Stage

p-value

Adjusted
OR (95% CI)
Regional
Stage

p-value

Adjusted
OR (95% CI)
Distant
Stage

p-value

Treatment Modality

No first course treatment

White, Non-Hispanic
African American

1.00
1.10 (1.06 1.14)

<0.0001

1.00
0.89 (0.800.98)

<0.0001

1.00
0.63 (0.57 0.71)

<0.0001

1.00
0.75 (0.67 0.83)

1.00
1.10 (0.991.22)

0.09

<0.0001

1.00
0.50 (0.34 0.75)

0.0007

<0.0001

1.00
0.34 (0.19 0.63)

0.0005

0.003

1.00
0.85 (0.77 0.95)

0.004

0.01

1.00
0.89 (0.75 1.07)

0.22

0.02

Surgery (singular or
multimodality)

White, Non-Hispanic
African American

1.00
0.66 (0.63 0.68)

Surgery only
White, Non-Hispanic
African American

1.00
0.65 (0.630.68)

Radiation Therapy (singular
or multimodality)
White, Non-Hispanic
African American

1.00
1.04 (1.01 1.07)

0.0128

1.00
1.14 (1.05 1.24)

0.75

1.00
1.16 (1.03 1.30)

Radiation Therapy only
White, Non-Hispanic
African American

1.00
1.00 (0.97 1.03)

Surgery and Radiation
White, Non-Hispanic

1.00

1.00
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1.00

African American

1.05 (0.83 1.33)

0.70

0.93 (0.75 1.15)

<0.0001

1.00
1.16 (1.06 1.27)

<0.0001

1.00
1.41 (1.24 1.61)

0.54 (0.15 1.89)

0.34

1.00
0.92 (0.84 1.01)

0.08

1.00
1.00 (0.92 1.10)

0.9641

0.01

1.00
0.86 (0.76 0.98)

0.03

0.001

1.00
0.74 (0.33 1.64)

0.45

0.50

Hormone Therapy (singular
or multimodality)
White, Non-Hispanic
African American

1.00
1.20 (1.16 1.24)

0.001

Hormone Therapy only
White, Non-Hispanic
African American
Radiation and Hormone
Therapy
White, Non-Hispanic
African American
Surgery and Hormone
Therapy
White, Non-Hispanic
African American

1.00
1.61 (1.52 1.71)

1.00
1.06 (1.03 1.11)

1.00
0.86 (0.75 0.98)

0.001

1.00
1.18 (1.03 1.34)

0.02

1.00
0.66 (0.52 0.85)

<0.0001

Surgery and Hormone
Therapy and Radiation
Therapy
White, Non-Hispanic

1.00

African American

1.22 (0.81 1.84)

1.00

0.3415

0.90 (0.69 1.19)

0.97

1.00
0.46 (0.23 0.91)

1.00

0.4717

0.995 (0.35
- 2.86)

0.9932

0.03

1.00
0.80 (0.63 1.01)

0.06

1.00
0.46 (0.14 1.55)

0.2118

Chemotherapy (singular or
multimodality)
White, Non-Hispanic
African American

1.00
0.99 (0.75 1.33)

Immunotherapy (singular or
multimodality)
White, Non-Hispanic
African American

1.00
1.07 (0.53 2.15)

1.00
0.86
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NA (n=12)

NA (n=12)

Other Therapy (singular or
multimodality)
White, Non-Hispanic
African American

1.00
0.68 (0.43 1.08)

0.098

1.00
1.38 (0.53 3.62)

0.5127

1.00
1.68 (0.96 2.96)

0.0706

Endocrine Therapy (singular
or multimodality)
White, Non-Hispanic
African American

1.00
2.32 (1.91 2.83)

<0.0001

1.00
2.24 (1.61 3.12)

<0.0001

1.00
1.40 (1.06 1.85)

<0.0001

1.00
1.54 (1.27 1.86)

<0.0001

Other Therapy (other tx
only, chemotherapy only,
endocrine therapy only or
immunotherapy only)
White, Non-Hispanic
African American

1.00
1.49 (1.28 1.73)

0.02

1.00
1.21 (1.04 1.40)

0.0125

*Adjusted for year of diagnosis, marital status, age at diagnosis, tumor grade, health insurance status and vital status
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Table 14. Summary of Significant Treatment Patterns by Stage at Diagnosis - based on
adjusted OR (95% CI)
Localized Disease
AA men more likely
(statistically significant)

AA men less likely
(statistically significant)

No first course treatment

*+Surgery only or surgery in
combo

Radiation Therapy

Surgery and Hormone
Therapy

Hormone therapy only or in
combo
Radiation and Hormone
Therapy
*Endocrine Therapy
*Other Therapy
Regional Disease
AA men more likely
(statistically significant)

AA men less likely
(statistically significant)

Radiation Therapy only or
Radiation in combo

No first course treatment

Hormone Therapy only or
Hormone Therapy in combo

*+Surgery only or surgery in
combo

Radiation and Hormone
Therapy

Surgery and Hormone
Therapy

*Endocrine Therapy

Chemo

*Other Therapy
Distant Disease
AA men more likely
(statistically significant)

AA men less likely
(statistically significant)

*Endocrine Therapy

*+Surgery only or surgery in
combo

*Other Therapy

Radiation Therapy
Radiation and Hormone
Therapy

*=common treatment pattern(s) between all stages at diagnosis
+=common treatment pattern(s) between stage at diagnosis, age at diagnosis and tumor grade
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Table 15. Summary of Significant Treatment Patterns by Tumor Grade –based on adjusted OR
and 95% CI
Grade 1
AA men more likely
(statistically
significant)

AA men less likely
(statistically
significant)

*Radiation only and
radiation in combination
with other treatment
modalities

No first course
treatment

*Hormone only and
hormone in combination
with other treatment
modalities

*+Surgery only or
surgery in combination
with other treatment
modalities

Other treatment
Grade 2
AA men more likely
(statistically
significant)

AA men less likely
(statistically
significant)

*Radiation only or
radiation in combination
with other treatment
modalities
*Hormone only or
hormone in combination
with other treatment
modalities
Radiation and hormone
therapy
Endocrine treatment only
or in combination with
other treatment
modalities
Other treatment

*+Surgery only or
surgery in combination
with other treatment
modalities

Grade 3
AA men more likely
(statistically
significant)

AA men less likely
(statistically
significant)

No first course treatment

*+Surgery only or
surgery in combination
with other treatment
modalities

*Hormone only or
hormone in combination
with other treatment

Radiation only
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modalities

*Radiation and hormone

Radiation and surgery

Endocrine therapy only
or in combination with
other treatment
modalities

Surgery and hormone
therapy

Other treatment

Surgery and hormone
and radiation
Chemotherapy only or
chemotherapy in
combination with other
treatment modalities
Grade 4

AA men more likely
(statistically
significant)

AA men less likely
(statistically
significant)

No significance

No significance

*=common treatment pattern(s) between all tumor grades
+=common treatment pattern(s) between stage at diagnosis, age at diagnosis and tumor grade
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Table 16. Adjusted Odds Ratios* (OR) and 95% Confidence Intervals of Prostate Cancer
Patients by Treatment, Race/Ethnicity and Tumor Grade.

Treatment Modality
No first course
treatment
White, Non-Hispanic
African American
Surgery (singular or
multimodality)
White, Non-Hispanic
African American

Adjusted
OR (95%
CI)
Tumor
Grade 1

1.00
0.87
(0.80 0.94)

1.00
0.55
(0.46 0.67)

p-value

0.0006

Adjusted
OR (95%
CI)
Tumor
Grade 2

1.00
1.02
(0.98 1.07)

<0.0001

1.00
0.68
(0.65 0.71)

<0.0001

1.00
0.68
(0.64 0.71)

0.0017

1.00
1.09
(1.05 1.13)

p-value

Adjusted
OR (95%
CI)
Tumor
Grade 3

0.30

1.00
1.27
(1.20 1.35)

<0.0001

1.00
0.57
(0.53 0.60)

<0.0001

1.00
0.60
(0.57 0.63)

<0.0001

1.00
0.99
(0.94 1.03)

p-value

Adjusted
OR (95%
CI)
Tumor
Grade 4

p-value

<0.0001

1.00
0.76
(0.55 1.05)

0.0923

<0.0001

1.00
0.78
(0.50 1.21)

0.27

<0.0001

1.00
0.95
(0.59 1.53)

0.8189

0.50

1.00
0.89
(0.67 1.18)

0.42

Surgery only
White, Non-Hispanic
African American

1.00
0.54
(0.44 0.65)

Radiation Therapy
(singular or
multimodality)
White, Non-Hispanic
African American

1.00
1.14
(1.05 1.24)

Radiation Therapy only
White, Non-Hispanic

African American

1.00
1.13
(1.03 1.23)

1.00

0.0065

1.04
(1.002 1.08)

1.00

1.00

0.04

0.94
(0.90 0.99)

0.03

0.88
(0.59 1.31)

0.53

0.99

1.00
0.71
(0.57 0.88)

0.002

1.00
0.50
(0.14 1.81)

0.29

Surgery and Radiation
White, Non-Hispanic
African American

1.00
0.60
(0.17 2.10)

0.42

1.00
1.00
(0.79 1.26)

Hormone Therapy
(singular or
multimodality)
White, Non-Hispanic

1.00

1.00
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1.00

1.00

African American

1.23
(1.09 1.38)

0.0007

1.22
(1.17 1.27)

<0.0001

1.20
(1.15 1.26)

<0.0001

1.00
1.43
(1.34 1.54)

0.0006

1.00
1.08
(1.02 1.14)

<0.0001

1.23
(0.94 1.62)

0.14

<0.0001

1.00
1.31
(0.96 1.79)

0.093

1.00
1.01
(0.71 1.46)

0.94

1.00
0.54
(0.16 1.84)

0.32

0.0064

1.00
0.84
(0.23 3.05)

0.8

0.0002

1.00
1.44
(0.71 2.91)

0.31

Hormone Therapy only
White, Non-Hispanic
African American
Radiation and Hormone
Therapy
White, Non-Hispanic
African American
Surgery and Hormone
Therapy
White, Non-Hispanic
African American

1.00
1.39
(1.18 1.63)

1.00
1.02
(0.86 1.20)

1.00
0.89
(0.47 1.68)

<0.0001

1.00
1.50
(1.40 1.61)

0.85

1.00
1.09
(1.04 1.14)

0.72

1.00
0.87
(0.75 1.01)

NA (n=7)

1.00
1.10
(0.77 1.58)

0.0014

1.00
1.04
(0.76 1.42)

0.47

1.00
0.88
(0.31 2.50)

0.58

1.00
0.98
(0.62 1.55)

0.07

1.00
0.62
(0.51 0.76)

0.004

<0.0001

Surgery and Hormone
Therapy and Radiation
Therapy
White, Non-Hispanic

1.00

African American
Chemotherapy (singular
or multimodality)

NA (n=7)

White, Non-Hispanic
African American
Immunotherapy
(singular or
multimodality)
White, Non-Hispanic
African American
Other Therapy (singular
or multimodality)
White, Non-Hispanic
African American

1.00
2.44
(1.41 4.20)

1.00
0.48
(0.06 3.61)

1.00
1.32
(0.50 3.44)

Endocrine Therapy
(singular or
multimodality)
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1.00
0.67
(0.50 0.89)

0.60

0.82

1.00
0.62
(0.49 0.80)

0.81

1.00
0.77
(0.34 1.71)

0.92

1.00
0.97
(0.57 1.65)

1.00
0.51

NA

NA

1.00
0.90

NA

NA

White, Non-Hispanic
African American
Other Therapy (other tx
only, chemotherapy
only, endocrine therapy
only or immunotherapy
only)
White, Non-Hispanic
African American

1.00
1.53
(0.80 2.92)

1.00
1.85
(1.27 2.69)

0.1956

0.0013

1.00
2.03
(1.65 2.49)

1.00
1.50
(1.28 1.76)

<0.0001

1.00
1.95
(1.65 2.30)

<0.0001

1.00
1.26
(1.11 1.44)

<0.0001

1.00
1.97
(0.89 4.36)

0.0006

1.00
1.64
(0.96 2.81)

0.0963

0.070

*Adjusted for year of diagnosis, marital status, age at diagnosis, stage at diagnosis, health insurance status and vital
status
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Table 17. Summary of Significant Treatment Patterns by Age at Diagnosis – based on adjusted
OR and 95% CI
Age <50
AA men more
likely (statistically
significant)

AA men less likely
(statistically
significant)

Radiation only or
radiation in
combination with
other treatment
modalities

*+Surgery only or
surgery in
combination with
other treatment
modalities

*Hormone only or
hormone therapy in
combination with
other treatment
modalities
Radiation and
hormone therapy
Age 50-64
AA men more
likely (statistically
significant)

AA men less likely
(statistically
significant)

No first course
treatment

*+Surgery only or
surgery in
combination with
other treatment
modalities

Radiation only or
radiation in
combination with
other treatment
modalities

Surgery and
radiation

*Hormone therapy
only or hormone
therapy in
combination with
other treatment
modalities

Surgery and
hormone and
radiation

Radiation and
hormone therapy
Endocrine therapy
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Age 65-74
AA men more
likely (statistically
significant)

AA men less likely
(statistically
significant)

*Hormone therapy

*+Surgery only or
surgery in
combination with
other treatment
modalities

Endocrine therapy
Other treatment
Age 75+
AA men more
likely (statistically
significant)

AA men less likely
(statistically
significant)

No first course
treatment

*+Surgery only or
surgery in
combination with
other treatment
modalities

Radiation only or
radiation in
combination with
other treatment
modalities

Radiation and
hormone therapy

*Hormone therapy
only
Endocrine therapy
Other treatment

*=common treatment pattern(s) between all ages at diagnosis
+=common treatment pattern(s) between stage at diagnosis, age at diagnosis and tumor grade
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Table 18. Adjusted Odds Ratios* (OR) and 95% Confidence Intervals of Prostate Cancer
Patients by Treatment, Race/Ethnicity and Age at Diagnosis

Treatment Modality

Adjusted
OR (95%
CI) Age
at
diagnosis
<50

p-value

Adjusted
OR (95%
CI) Age
at
diagnosis
50-64

p-value

Adjusted
OR (95%
CI) Age
at
diagnosis
65-74

p-value

Adjusted
OR (95%
CI) Age
at
diagnosis
75+

p-value

No first course
treatment

White, Non-Hispanic
African American

1.00
1.03
(0.84 1.25)

0.79

1.00
1.09
(1.04 1.15)

0.0012

1.00
1.05
(0.99 1.10)

1.00
1.19
(1.11 1.27)

<0.0001

<0.0001

1.00
0.56
(0.44 0.72)

<0.0001

<0.0001

1.00
0.57
(0.44 0.74)

<0.0001

0.1

1.00
0.72
(0.67 0.77)

<0.0001

0.88

1.00
0.83
(0.77 -

<0.0001

0.058

Surgery (singular or
multimodality)

White, Non-Hispanic
African American

1.00
0.71
(0.61 0.82)

<0.0001

1.00
0.65
(0.62 0.68)

<0.0001

1.00
0.67
(0.64 0.70)

<0.0001

1.00
1.23
(1.18 1.28)

<0.0001

1.00
1.11
(1.06 -

<0.0001

1.00
0.62
(0.58 0.65)

<0.0001

1.00
0.62
(0.58 0.66)

<0.0001

1.00
1.03
(0.99 1.08)

<0.0001

1.00
1.00
(0.96 -

Surgery only

White, Non-Hispanic
African American

1.00
0.70
(0.61 0.81)

Radiation Therapy
(singular or
multimodality)
White, Non-Hispanic
African American
Radiation Therapy
only
White, Non-Hispanic
African American

1.00
1.48
(1.27 1.72)

1.00
1.46
(1.21 -
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1.75)

1.16)

1.04)

0.89)

1.00
1.02
(0.60 1.74)

0.93

1.00
0.81
(0.67 0.98)

1.00
0.82
(0.61 1.11)

0.20

1.00
0.28
(0.04 2.04)

0.21

0.04

1.00
1.40
(1.33 1.47)

<0.0001

1.00
0.95
(0.89 1.01)

0.12

Surgery and
Radiation
White, Non-Hispanic
African American

0.03

Hormone Therapy
(singular or
multimodality)
White, Non-Hispanic
African American

1.00
1.24
(1.01 1.53)

<0.0001

1.00
1.21
(1.16 1.26)

<0.0001

1.00
0.99
(0.96 1.04)

Hormone Therapy
only
White, Non-Hispanic
African American

1.00
1.46
(1.21 1.75)

<0.0001

1.00
1.11
(1.06 1.16)

0.88

1.00
0.83
(0.77 0.89)

<0.0001

Radiation and
Hormone Therapy
White, Non-Hispanic

African American

1.00

1.00

1.43
(1.09 1.86)

0.0095

1.36
(1.28 1.44)

0.79

1.00
0.73
(0.55 0.98)

0.79

1.00
0.73
(0.55 0.98)

1.00

<0.0001

1.05
(0.998 1.10)

1.00

0.061

0.73
(0.66 0.79)

0.27

1.00
1.05
(0.31 3.58)

0.94

0.27

1.00
1.05
(0.31 3.58)

0.94

<0.0001

Surgery and
Hormone Therapy
White, Non-Hispanic
African American

1.00
1.11
(0.52 2.36)

0.034

1.00
0.80
(0.53 1.20)

0.03

1.00
0.80
(0.53 1.20)

Surgery and
Hormone Therapy
and Radiation
Therapy
White, Non-Hispanic
African American

1.00
1.11
(0.52 2.36)

Chemotherapy
(singular or
multimodality)

170

White, Non-Hispanic

African American

1.00

1.00

1.00

1.00

1.24
(0.55 2.77)

0.60

0.79
('0.60 1.04)

0.09

0.86
(0.64 1.16)

0.83
(0.55 1.27)

0.39

NA

1.00
1.12
(0.45 2.78)

0.81

1.00
0.47
(0.15 1.51)

1.00
0.60
(0.15 2.52)

0.49

0.78

1.00
0.80
(0.45 1.42)

1.00
1.35
(0.74 2.48)

0.33

0.31

Immunotherapy
(singular or
multimodality)
White, Non-Hispanic
African American

1.00
NA

0.20

Other Therapy
(singular or
multimodality)
White, Non-Hispanic
African American

1.00
0.85
(0.17 4.30)

0.85

1.00
0.92
(0.53 1.62)

0.47

1.00
1.86
(1.40 2.46)

0.27

1.00
1.18
(0.99 1.42)

0.44

Endocrine Therapy
(singular or
multimodality)
White, Non-Hispanic
African American

1.00
1.58
(0.46 5.39)

<0.0001

1.00
1.86
(1.50 2.31)

<0.0001

1.00
2.05
(1.70 2.48)

<0.0001

1.00
1.67
(1.42 1.97)

<0.0001

Other Therapy (other
tx only,
chemotherapy only,
endocrine therapy
only or
immunotherapy only)
White, Non-Hispanic
African American

1.00
1.41
(0.77 2.61)

0.07

1.00
1.29
(1.09 1.52)

0.003

*Adjusted for year of diagnosis, marital status, tumor grade, stage at diagnosis, health insurance status and vital
status
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Appendix O
List of Abbreviations
AA: African American
AAFP: American Academy of Family Physicians
AARR: Age-adjusted relative risk
ACoS: American College of Surgeons
ACS: American Cancer Society
ADT: Androgen-deprived therapy
AHCA: Agency for Healthcare Administration
AJCC: American Joint Committee on Cancer TNM Staging System
AOR: Adjusted odds ratio
ASCO: American Society of Clinical Oncology
BCC: Basal cell carcinoma of the skin
BH: Black Hispanic
BPH: Benign prostate hyperplasia
CDC: Centers for Disease Control and Prevention
CMS: Centers of Medicare and Medicaid Services
COPH: College of Public Health at the University of South Florida
CS: Collaborative Staging
CT: Computed Tomography Scan
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CTR: Certified Tumor Registrar
CY: Calendar year
DAM: Data Acquisition Manual
DOD: Department of Defense
DRE: Digital rectal examination
EOH: Environmental and Occupational Health
ERSPC: European Randomized Study of Screening for Prostate Cancer
FCDS: Florida Cancer Data System
FDA: Federal Drug Administration
FDOH: Florida Department of Health
FU: Follow-up
FY: Fiscal year
GWAS: Genome-wide Association Study
HPV: Human Papilloma Virus
Hx: History
IARC: International Agency for Research on Cancer
ICD-O-3: International Classification of Disease for Oncology, Third Edition
ICD-9-CM: International Classification of Diseases, Ninth Edition, Clinical Modification
ICD-10-CM: International Classification of Disease, Tenth Edition, Clinical Modification
IRB: Institutional Review Board
MDS: Myelodysplastic Syndrome
ML: Milliliter
MRI: Magnetic Resonance Imaging
NCCN: National Comprehensive Cancer Network
NCDB : National Cancer Data Base
NCI : National Cancer Institute
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NHW: Non-Hispanic White
NPCR: National Program or Cancer Registries
OR: odds ratio
PADT: Primary androgen deprived therapy
PIN III: High grade prostatic intraepithelial neoplasia
PLCO: Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial
PrCa: Prostate cancer
PSA: Prostate Specific Antigen test
PH: Public Health
ROC: Receiver Operating Characteristic Curve
RR: Relative Risk
SAS: Statistical Analysis Software
Se: Selenium
SEER: Surveillance, Epidemiology and End Results
SES: Socioeconomic status
SNP: single nucleotide polymorphism
SSA: Social Security Administration
STI: Sexually Transmitted Infections
TRUS: Transrectal ultrasound guided biopsy of the prostate
USF: University of South Florida
USFPS TF: United States Preventative Services Task Force
UTI: Urinary Tract Infection
VA: Veterans Administration
WHO: World Health Organization
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